

A. ORIGIN OF THE REPORT

A1		Name of contracting Party: Philippines
A3k		Web page https://www.doh.gov.ph/tobacco-control-hub
1		Period of reporting:
	1	Start date April 2020
	1	End date March 2023

B1. TOBACCO CONSUMPTION

B1		Prevalence of tobacco use
B11		Smoking prevalence in the adult population (all) (Please provide prevalence data for total adult population, and identify the age considered, e.g. 15 years old and over, 18-64 years; see B112)
1_SQ001		Current smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 33.3
	1_SQ002	MALE [Average number of the most-consumed smoking tobacco product used per day] 9.8
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 3.7
	2_SQ002	FEMALE [Average number of the most-consumed smoking tobacco product used per day] 6.7
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 18.5
	3_SQ002	TOTAL (males and females) [Average number of the most-consumed smoking tobacco product used per day] 9.5
1_SQ001		Daily smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 26.3
	1_SQ002	MALE [Average number of the most-consumed smoking tobacco product used per day] 10.8
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 2.6
	2_SQ002	FEMALE [Average number of the most-consumed smoking tobacco product used per day] 6.7
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 14.5
	3_SQ002	TOTAL (males and females) [Average number of the most-consumed smoking tobacco product used per day] 10.5
1_SQ001		Occasional smokers

	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 7.0
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 1.1
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 4.1
1_SQ001		Former smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 20.9
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 34.2
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 22.3
1_SQ001		Never smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 53.9
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 92.2
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 73.0
B111		Please indicate the smoking tobacco products included in calculating prevalence for question B11: The smoking tobacco products included in calculating the prevalence for question B11 were the following: cigarettes (e.g., manufactured, hand-rolled, and kretek), waterpipe, pipes, cigars/cheroots/cigarillos, and other reported smoking tobacco products.
1_SQ001		Please indicate the age range to which the data used to answer question B11 refer:
	1_SQ001	Age range [From] 15
	1_SQ002	Age range [To] 100
B113A		Please indicate the year of the data used to answer question B11: 2021
B113B		Please indicate the source of the data used to answer question B11: 2021 Philippine Global Adult Tobacco Survey (GATS)
SQ001		Please provide the definitions of “current smoker”, “daily smoker”, “occasional smoker”, “former smoker” and “never smoker” used in this report.

	SQ001	Current smoker Includes both daily and occasional (less than daily) smoker
	SQ002	Daily smoker Smoking at least one tobacco product everyday or nearly everyday over a period of a month or more
	SQ003	Occasional smoker Less than daily smokers
	SQ004	Former smoker Smoked tobacco in the past but currently do not smoke
	SQ005	Never smoker Does not smoke at all
B115		Please provide a brief explanation of the trend in smoking prevalence in the adult population in the past two years or since submission of your last report. Current cigarette smoking prevalence significantly decreased from 22.5 in 2015 to 18.3 in 2021. This represents a 18.7% relative decline of current cigarette smoking prevalence. For the years 2009, 2015, and 2021 respectively, a decreasing trend (28.5 ? 22.7 ? 18.5) in current tobacco smoking prevalence for the general adult population is observed. This is also the same case for both trends in the prevalence among men (47.6 ? 40.3 ? 33.3) and women (9.0 ? 5.3 ? 3.7) who are currently smoking tobacco.
B12a_B12x1		Smoking prevalence in the adult population (by age groups)(If data are available, please provide prevalence data by age group, and identify the age group considered, preferably by 10-year categories, e.g. 25-34, 35-44 years)
	B12a_B12x1	MALES - current smokers1 [Range - start age] 15
	B12a_B12x3	MALES - current smokers1 [Range - end age] 24
	B12a_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 18.2
	B12b_B12x1	MALES - current smokers1 [Range - start age] 25
	B12b_B12x3	MALES - current smokers1 [Range - end age] 44
	B12b_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 41.7
	B12c_B12x1	MALES - current smokers1 [Range - start age] 45
	B12c_B12x3	MALES - current smokers1 [Range - end age] 64
	B12c_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in

		prevalence data)] 37.5
	B12d_B12x1	MALES - current smokers1 [Range - start age] 65
	B12d_B12x3	MALES - current smokers1 [Range - end age] 100
	B12d_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 26.3
	B12e_B12x1	MALES - current smokers1 [Range - start age]
	B12e_B12x3	MALES - current smokers1 [Range - end age]
	B12e_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12ee_B12x1	MALES - current smokers1 [Range - start age]
	B12ee_B12x3	MALES - current smokers1 [Range - end age]
	B12ee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12eee_B12x1	MALES - current smokers1 [Range - start age]
	B12eee_B12x3	MALES - current smokers1 [Range - end age]
	B12eee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12eeee_B12x1	MALES - current smokers1 [Range - start age]
	B12eeee_B12x3	MALES - current smokers1 [Range - end age]
	B12eeee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12eeee_B12x1	MALES - current smokers1 [Range - start age]
	B12eeee_B12x3	MALES - current smokers1 [Range - end age]
	B12eeee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12eeee_B12x1	MALES - current smokers1 [Range - start age]
	B12eeee_B12x3	MALES - current smokers1 [Range - end age]
	B12eeee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12f_B12x1	FEMALES - current smokers1 [Range - start age] 15
	B12f_B12x3	FEMALES - current smokers1 [Range - end age] 24

	B12f_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 0.9
	B12g_B12x1	FEMALES - current smokers1 [Range - start age] 25
	B12g_B12x3	FEMALES - current smokers1 [Range - end age] 44
	B12g_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 3.2
	B12h_B12x1	FEMALES - current smokers1 [Range - start age] 45
	B12h_B12x3	FEMALES - current smokers1 [Range - end age] 64
	B12h_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 5.5
	B12i_B12x1	FEMALES - current smokers1 [Range - start age] 65
	B12i_B12x3	FEMALES - current smokers1 [Range - end age] 100
	B12i_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 8.6
	B12j_B12x1	FEMALES - current smokers1 [Range - start age]
	B12j_B12x3	FEMALES - current smokers1 [Range - end age]
	B12j_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12jj_B12x1	FEMALES - current smokers1 [Range - start age]
	B12jj_B12x3	FEMALES - current smokers1 [Range - end age]
	B12jj_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12jjj_B12x1	FEMALES - current smokers1 [Range - start age]
	B12jjj_B12x3	FEMALES - current smokers1 [Range - end age]

	B12jjj_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12jjjj_B12x1	FEMALES - current smokers1 [Range - start age]
	B12jjjj_B12x3	FEMALES - current smokers1 [Range - end age]
	B12jjjj_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12k_B12x1	TOTAL (males and females) - current smokers1 [Range - start age] 15
	B12k_B12x3	TOTAL (males and females) - current smokers1 [Range - end age] 24
	B12k_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 9.8
	B12l_B12x1	TOTAL (males and females) - current smokers1 [Range - start age] 25
	B12l_B12x3	TOTAL (males and females) - current smokers1 [Range - end age] 44
	B12l_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 22.8
	B12m_B12x1	TOTAL (males and females) - current smokers1 [Range - start age] 45
	B12m_B12x3	TOTAL (males and females) - current smokers1 [Range - end age] 64
	B12m_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 21.5
	B12n_B12x1	TOTAL (males and females) - current smokers1 [Range - start age] 65
	B12n_B12x3	TOTAL (males and females) - current smokers1 [Range - end age] 100
	B12n_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 16.2
	B12o_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]

	B12o_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
	B12o_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12oo_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]
	B12oo_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
	B12oo_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12ooo_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]
	B12ooo_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
	B12ooo_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12oooo_B12x 1	TOTAL (males and females) - current smokers1 [Range - start age]
	B12oooo_B12x 3	TOTAL (males and females) - current smokers1 [Range - end age]
	B12oooo_B12x 2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B121		<p>Please indicate the smoking tobacco products included in calculating prevalence for question B12:</p> <p>he smoking tobacco products included in calculating the prevalence for question B12 were the following: cigarettes (e.g., manufactured, hand-rolled, and kretek), waterpipe, pipes, cigars/cheroots/cigarillos, and other reported smoking tobacco products.</p>
B122A		<p>Please indicate the year of the data used to answer question B12:</p> <p>2021</p>
B122B		<p>Please indicate the source of the data used to answer question B12:</p> <p>2021 Philippines Global Adult Tobacco Survey (GATS)</p>
B123		<p>Please provide a brief explanation of the trend in current smoking prevalence by age group in the past two years or since submission of your last report, if data are available.</p> <p>The trend in current smoking prevalence by age group from 2015 to 2021 is decreasing for all age groups.</p>
B13		<p>Prevalence of smokeless tobacco use in the adult population (all) (Please provide prevalence data for total adult population, and identify the age considered in B132, e.g. 15 years old and over, 18–64 years; see B132)</p>

1_B13x1		Males
	1_B13x1	Current users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 2.3
	2_B13x1	Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 1.5
	3_B13x1	Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 0.8
	4_B13x1	Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 0.3
	5_B13x1	Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 96.1
1_B13x1		Females
	1_B13x1	Current users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 0.7
	2_B13x1	Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 0.4
	3_B13x1	Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 0.4
	4_B13x1	Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 0.1
	5_B13x1	Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 98.9
1_B13x1		TOTAL (males and females)
	1_B13x1	Current users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 1.5
	2_B13x1	Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 0.9
	3_B13x1	Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]

		0.6
	4_B13x1	Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 0.2
	5_B13x1	Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)] 97.5
B131		Please indicate the smokeless tobacco products included in calculating prevalence for question B13: The smokeless tobacco products included in calculating prevalence for question B13 were: chewing tobacco, snuff tobacco, betel quid with tobacco.
1_SQ001		Please indicate the age range to which the data used to answer question B13 refer:
	1_SQ001	Age range [From] 15
	1_SQ002	Age range [To] 100
B133A		Please indicate the year of the data used to answer question B13: 2021
B133B		Please indicate the source of the data used to answer question B13: 2021 Philippines Global Adult Tobacco Survey (GATS)
SQ001		Please provide the definitions of “current user”, “daily user”, “occasional user”, “former user” and “never user” (of smokeless tobacco products) used in this report in the space below.
	SQ001	Current user Includes both daily and occasional
	SQ002	Daily user Use smokeless tobacco at least one time everyday or nearly everyday over a period of a month or more
	SQ003	Occasional user Less than daily user
	SQ004	Former user Use smokeless tobacco in the past but is currently not a user of smokeless tobacco
	SQ005	Never user Does not use smokeless tobacco at all
B135		Please provide a brief explanation of the trend in smokeless tobacco use in the adult population in the past two years or since submission of your last report. The trend in the current use of smokeless tobacco from 2015 to 2021 is decreasing in general, and across sexes. For the years 2009, 2015, and 2021 respectively, a decreasing trend (2.0 ? 1.7 ? 1.5) in current smokeless tobacco user prevalence for the general adult population is observed. This is also the same case for both trends in the prevalence among men (2.8 ? 2.7 ? 2.3) and women (1.2 ? 0.7 ? 0.7) who are currently smokeless tobacco users.
B12a_B12x1		Prevalence of smokeless tobacco use in the adult population (current users) by age group

		(by age groups)(If data are available, please provide prevalence data by age group, and identify the age group considered, preferably by 10-year categories, e.g. 25-34, 35-44 years)
	B12a_B12x1	MALES - current users2 [Age group (adults)]
	B12a_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12b_B12x1	MALES - current users2 [Age group (adults)]
	B12b_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12c_B12x1	MALES - current users2 [Age group (adults)]
	B12c_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12d_B12x1	MALES - current users2 [Age group (adults)]
	B12d_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12e_B12x1	MALES - current users2 [Age group (adults)]
	B12e_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12ee_B12x1	MALES - current users2 [Age group (adults)]
	B12ee_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12eee_B12x1	MALES - current users2 [Age group (adults)]
	B12eee_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12eeee_B12x 1	MALES - current users2 [Age group (adults)]
	B12eeee_B12x 2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]

	B12f_B12x1	FEMALES - current users2 [Age group (adults)]
	B12f_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12g_B12x1	FEMALES - current users2 [Age group (adults)]
	B12g_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12h_B12x1	FEMALES - current users2 [Age group (adults)]
	B12h_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12i_B12x1	FEMALES - current users2 [Age group (adults)]
	B12i_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12j_B12x1	FEMALES - current users2 [Age group (adults)]
	B12j_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12jj_B12x1	FEMALES - current users2 [Age group (adults)]
	B12jj_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12jjj_B12x1	FEMALES - current users2 [Age group (adults)]
	B12jjj_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12jjjj_B12x1	FEMALES - current users2 [Age group (adults)]
	B12jjjj_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12k_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]

	B12k_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12l_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12l_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12m_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12m_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12n_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12n_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12o_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12o_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12oo_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12oo_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12ooo_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12ooo_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12oooo_B12x 1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12oooo_B12x 2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B141		Please indicate the smokeless tobacco products included in the answer to question B14:
B142A		Please indicate the year of the data used to answer question B14: 2021

B142B		Please indicate the source of the data used to answer question B14:
B143		<p>Please provide a brief explanation of the trend in current use of smokeless tobacco by adult age groups in the past two years or since submission of your last report.</p> <p>The 2021 GATS Country Report did not include data on prevalence of smokeless tobacco use by age group because of its low prevalence; thus, further analysis as to age group is not needed by the country</p>
B15a_B15x1		Tobacco use by ethnic group(s) (please include all smoking or smokeless tobacco products in prevalence data)
	B15a_B15x1	Current users 3 [Ethnic group(s)]
	B15a_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15a_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15a_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
	B15b_B15x1	Current users 3 [Ethnic group(s)]
	B15b_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15b_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15b_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
	B15c_B15x1	Current users 3 [Ethnic group(s)]
	B15c_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15c_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15c_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
	B15d_B15x1	Current users 3 [Ethnic group(s)]
	B15d_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15d_B15x3	Current users 3 [FEMALES - Prevalence (%)]

	B15d_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
	B15e_B15x1	Current users 3 [Ethnic group(s)]
	B15e_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15e_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15e_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
B151		Please indicate the tobacco products included in the answer to question B15:
1_SQ001		Please indicate the age range to which the data used to answer question B15 refer:
	1_SQ001	Age range [From]
	1_SQ002	Age range [To]
B153A		Please indicate the year of the data used to answer question B15:
B153B		Please indicate the source of the data used to answer question B15:
B16a_B16x1		Tobacco use by young persons (please include all smoking or smokeless tobacco products in prevalence data)
	B16a_B16x1	BOYS - Current users 4 [Age range] 13-15
	B16a_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)] 16.2
	B16a_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)] 4.3
	B16a_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)] 4.7
	B16b_B16x1	BOYS - Current users 4 [Age range]
	B16b_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16b_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]

	B16b_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16c_B16x1	BOYS - Current users 4 [Age range]
	B16c_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16c_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16c_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16d_B16x1	BOYS - Current users 4 [Age range]
	B16d_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16d_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16d_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16e_B16x1	BOYS - Current users 4 [Age range]
	B16e_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16e_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16e_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16ee_B16x1	BOYS - Current users 4 [Age range]
	B16ee_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16ee_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16ee_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16eee_B16x1	BOYS - Current users 4 [Age range]
	B16eee_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]

B16eee_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16eee_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
B16eeee_B16x 1	BOYS - Current users 4 [Age range]
B16eeee_B16x 2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16eeee_B16x 3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16eeee_B16x 4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
B16f_B16x1	GIRLS - Current users 4 [Age range] 13-15
B16f_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)] 5.6
B16f_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)] 1.7
B16f_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)] 1.7
B16g_B16x1	GIRLS - Current users 4 [Age range]
B16g_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16g_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16g_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
B16h_B16x1	GIRLS - Current users 4 [Age range]
B16h_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16h_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16h_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
B16i_B16x1	GIRLS - Current users 4 [Age range]

	B16i_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16i_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16i_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16j_B16x1	GIRLS - Current users 4 [Age range]
	B16j_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16j_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16j_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16jj_B16x1	GIRLS - Current users 4 [Age range]
	B16jj_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16jj_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16jj_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16jjj_B16x1	GIRLS - Current users 4 [Age range]
	B16jjj_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16jjj_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16jjj_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16jjjj_B16x1	GIRLS - Current users 4 [Age range]
	B16jjjj_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16jjjj_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16jjjj_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]

	B16k_B16x1	TOTAL (boys and girls) - Current users 4 [Age range] 13-15
	B16k_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)] 10.8
	B16k_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)] 3.0
	B16k_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)] 3.2
	B16l_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16l_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16l_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16l_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16m_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16m_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16m_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16m_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16n_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16n_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16n_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16n_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16o_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16o_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16o_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]

	B16o_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16oo_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16oo_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16oo_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16oo_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16ooo_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16ooo_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16ooo_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16ooo_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16oooo_B16x 1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16oooo_B16x 2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16oooo_B16x 3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16oooo_B16x 4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
B161		<p>Please indicate the tobacco products included in calculating prevalence for question B16:</p> <p>The tobacco products included in calculating prevalence for question B16 are the following: cigarettes (manufactured, hand rolled, and kretek), pipes, cigars, mini cigars/cigarillos, hookah/ waterpipes, bidis, shisha.</p>
B162A		<p>Please indicate the year of the data used to answer question B16:</p> <p>2019</p>
B162B		<p>Please indicate the source of the data used to answer question B16:</p> <p>2019 Philippine Global Youth Tobacco Survey (GYTS)</p>
B163		<p>Please provide the definition of “current smoking/tobacco use” used to answer question B16 in the space below.</p> <p>“Current tobacco use” is operationally defined as having “smoked tobacco anytime during the past 30 days.”</p>
B164		<p>Please provide a brief explanation of the trend in tobacco use by young persons in the past two years or since submission of your last report.</p> <p>Current cigarette smoking prevalence for young persons decreased from 12 in 2015 to 10 in 2019.</p>

		This represents a 16.7% relative decline of current cigarette smoking prevalence.
SQ001_SQ001		Male
	SQ001_SQ001	Prevalence (%) (please include all smoking tobacco products in prevalence data) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ001_SQ002	Prevalence (%) (please include all smoking tobacco products in prevalence data) [Average number of the most-consumed smoking tobacco product used per day]
	SQ002_SQ001	Average number of the most-consumed smoking tobacco product used per day [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ002_SQ002	Average number of the most-consumed smoking tobacco product used per day [Average number of the most-consumed smoking tobacco product used per day]
	SQ003_SQ001	Occasional smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ003_SQ002	Occasional smokers [Average number of the most-consumed smoking tobacco product used per day]
	SQ004_SQ001	Former smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ004_SQ002	Former smokers [Average number of the most-consumed smoking tobacco product used per day]
	SQ005_SQ001	Never smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ005_SQ002	Never smokers [Average number of the most-consumed smoking tobacco product used per day]
1_1		Use of novel and emerging tobacco and nicotine products
	1_1	Age range [Age range] 15-100
	1_2	Age range [Heated tobacco products (HTPs) - Prevalence (%)]
	1_3	Age range [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)] 3.6 (Current use of e-cigarette)
	1_4	Age range [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]

	1_5	Age range [Other products - Prevalence (%)]
	2_1	Heated tobacco products (HTPs) - Prevalence (%) [Age range] 15-100
	2_2	Heated tobacco products (HTPs) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
	2_3	Heated tobacco products (HTPs) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)] 0.5 (Current use of e-cigarette)
	2_4	Heated tobacco products (HTPs) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	2_5	Heated tobacco products (HTPs) - Prevalence (%) [Other products - Prevalence (%)]
	3_1	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Age range] 15-100
	3_2	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
	3_3	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)] 2.1 (Current use of e-cigarette)
	3_4	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	3_5	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Other products - Prevalence (%)]
	4_1	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Age range] 13-15
	4_2	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
	4_3	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)] 20.9 (Current use of e-cigarette)
	4_4	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	4_5	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Other products - Prevalence (%)]

	5_1	Other products - Prevalence (%) [Age range] 13-15
	5_2	Other products - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
	5_3	Other products - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)] 7.5 (Current use of e-cigarette)
	5_4	Other products - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	5_5	Other products - Prevalence (%) [Other products - Prevalence (%)]
	6_1	YOUNG PERSONS - Total (boys and girls) [Age range] 13-15
	6_2	YOUNG PERSONS - Total (boys and girls) [Heated tobacco products (HTPs) - Prevalence (%)]
	6_3	YOUNG PERSONS - Total (boys and girls) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)] 14.1 ((Current use of e-cigarette)
	6_4	YOUNG PERSONS - Total (boys and girls) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	6_5	YOUNG PERSONS - Total (boys and girls) [Other products - Prevalence (%)]
B171		Please indicate the year and source of the data used to answer question B17. 2021 Global Adult Tobacco Survey (GATS) and 2019 Global Youth Tobacco Survey (GYTS)
B172		Please provide a brief explanation of the trends – in adults and in young persons – in the use of novel and emerging tobacco and nicotine products in the past two years or since submission of your last report. There was an increase in prevalence of current e- cigarette smoking by adult persons by 61.5%, from 0.8% in 2015 to 2.1% in 2021. There was also an increase in prevalence of current e- cigarette smoking by young persons by 20.5%; from 11.7% in 2015 to 14.1% in 2019.

B2-B9. HEALTH, SOCIAL AND ECONOMIC INDICATORS

B2		Exposure to tobacco smoke
B21		Do you have any data on exposure to tobacco smoke in your population? Yes
B22		Please provide details in the space below (e.g. exposure by gender, at home, in the workplace, on public transport). -12.9% of adults who worked indoors (2.5 million adults) were exposed to tobacco smoke in enclosed areas at their workplace. -21.8% of adults (16.8 million adults) were exposed to tobacco smoke at home. -62.3% of adults (0.3 million adults) were exposed to tobacco smoke when visiting bars and nightclubs. -12.2% of adults (4.2 million adults) were exposed to tobacco smoke when using public transportation. -29.3% of students (13-15 years old) were exposed to tobacco smoke at home while 62.7% of students saw anyone smoking within school premises
B23A		Please indicate the year of the data used to answer question B21: 2021
B23B		Please indicate the source of the data used to answer question B21: 2021 Global Adult Tobacco Survey (GATS) and 2019 Global Youth Tobacco Survey (GYTS)
B3		Tobacco-related mortality
B31		Do you have information on tobacco-related mortality in your population? Yes
B32		What is the estimated total number of deaths attributable to tobacco use in your population? 112,112 estimated total number of deaths attributable to tobacco use
B33		If available, please provide any additional information on mortality attributable to tobacco use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction. Ischaemic heart disease (Male: 62171, Female: 43110, Total: 105281) Cerebrovascular disease (Male: 36593, Female: 27778, Total: 64381) Pneumonia (Male: 17621, Female: 16684, Total: 34,305) Hypertensive diseases (Male: 17002, Female: 14725, Total: 31727) Chronic lower respiratory infection (Male: 14691, Female: 5908, Total: 20599)
B34A		Please indicate the year of the data used to answer question B32 and 33: 2020
B34B		Please indicate the source of the data used to answer questions B32 and B33: B32: 2019 Global Burden of Disease Study B33: 2020 Philippine Health Statistics
B4		Tobacco-related costs
B41		Do you have information on the economic burden of tobacco use in your population, e.g. the overall cost of tobacco use imposed on your society? Yes
B42		Please provide details (e.g. direct (health care-related) and indirect costs and, if possible, the method used to estimate these costs).
B43A		Please indicate the year of the data used to answer question B42: 2015

B43B		Please indicate the source of the data used to answer question B42:
B5		Supply of tobacco and tobacco products (with reference to Articles 6.2(b), 20.4(c), and 15.5)
B51a_B51x1		Licit supply of tobacco products
	B51a_B51x1	Smoking tobacco products [Product] Cigarettes
	B51a_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)] Million packs (20 sticks/ pack)
	B51a_B51x3	Smoking tobacco products [Domestic production] 2, 971.1 (for domestic consumption)
	B51a_B51x4	Smoking tobacco products [Retail sales]
	B51a_B51x5	Smoking tobacco products [Exports] 1,733.8
	B51a_B51x6	Smoking tobacco products [Imports] 507.2
	B51b_B51x1	Smoking tobacco products [Product] Cigars
	B51b_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)] Thousand pieces
	B51b_B51x3	Smoking tobacco products [Domestic production] 254.4 (for domestic consumption)
	B51b_B51x4	Smoking tobacco products [Retail sales]
	B51b_B51x5	Smoking tobacco products [Exports] 2,712.4
	B51b_B51x6	Smoking tobacco products [Imports] 21.8
	B51c_B51x1	Smoking tobacco products [Product]
	B51c_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51c_B51x3	Smoking tobacco products [Domestic production]
	B51c_B51x4	Smoking tobacco products [Retail sales]

	B51c_B51x5	Smoking tobacco products [Exports]
	B51c_B51x6	Smoking tobacco products [Imports]
	B51cc_B51x1	Smoking tobacco products [Product]
	B51cc_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51cc_B51x3	Smoking tobacco products [Domestic production]
	B51cc_B51x4	Smoking tobacco products [Retail sales]
	B51cc_B51x5	Smoking tobacco products [Exports]
	B51cc_B51x6	Smoking tobacco products [Imports]
	B51ccc_B51x1	Smoking tobacco products [Product]
	B51ccc_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51ccc_B51x3	Smoking tobacco products [Domestic production]
	B51ccc_B51x4	Smoking tobacco products [Retail sales]
	B51ccc_B51x5	Smoking tobacco products [Exports]
	B51ccc_B51x6	Smoking tobacco products [Imports]
	B51cccc_B51x 1	Smoking tobacco products [Product]
	B51cccc_B51x 2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51cccc_B51x 3	Smoking tobacco products [Domestic production]
	B51cccc_B51x 4	Smoking tobacco products [Retail sales]
	B51cccc_B51x 5	Smoking tobacco products [Exports]

	B51cccc_B51x6	Smoking tobacco products [Imports]
	B51d_B51x1	Smokeless tobacco products [Product] Chewing tobacco
	B51d_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)] Thousand kilograms
	B51d_B51x3	Smokeless tobacco products [Domestic production] 1,135.5 (for domestic consumption)
	B51d_B51x4	Smokeless tobacco products [Retail sales]
	B51d_B51x5	Smokeless tobacco products [Exports]
	B51d_B51x6	Smokeless tobacco products [Imports] 2.5
	B51e_B51x1	Smokeless tobacco products [Product]
	B51e_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B51e_B51x3	Smokeless tobacco products [Domestic production]
	B51e_B51x4	Smokeless tobacco products [Retail sales]
	B51e_B51x5	Smokeless tobacco products [Exports]
	B51e_B51x6	Smokeless tobacco products [Imports]
	B51f_B51x1	Smokeless tobacco products [Product]
	B51f_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B51f_B51x3	Smokeless tobacco products [Domestic production]
	B51f_B51x4	Smokeless tobacco products [Retail sales]
	B51f_B51x5	Smokeless tobacco products [Exports]
	B51f_B51x6	Smokeless tobacco products [Imports]

	B51ff_B51x1	Smokeless tobacco products [Product]
	B51ff_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B51ff_B51x3	Smokeless tobacco products [Domestic production]
	B51ff_B51x4	Smokeless tobacco products [Retail sales]
	B51ff_B51x5	Smokeless tobacco products [Exports]
	B51ff_B51x6	Smokeless tobacco products [Imports]
	B51fff_B51x1	Smokeless tobacco products [Product]
	B51fff_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B51fff_B51x3	Smokeless tobacco products [Domestic production]
	B51fff_B51x4	Smokeless tobacco products [Retail sales]
	B51fff_B51x5	Smokeless tobacco products [Exports]
	B51fff_B51x6	Smokeless tobacco products [Imports]
	B51ffff_B51x1	Smokeless tobacco products [Product]
	B51ffff_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B51ffff_B51x3	Smokeless tobacco products [Domestic production]
	B51ffff_B51x4	Smokeless tobacco products [Retail sales]
	B51ffff_B51x5	Smokeless tobacco products [Exports]
	B51ffff_B51x6	Smokeless tobacco products [Imports]
	B51g_B51x1	Other tobacco products [Product] Heated tobacco

	B51g_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)] Million packs
	B51g_B51x3	Other tobacco products [Domestic production]
	B51g_B51x4	Other tobacco products [Retail sales]
	B51g_B51x5	Other tobacco products [Exports]
	B51g_B51x6	Other tobacco products [Imports] 8.8
	B51h_B51x1	Other tobacco products [Product] Vapor products
	B51h_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)] Thousand ml.
	B51h_B51x3	Other tobacco products [Domestic production]
	B51h_B51x4	Other tobacco products [Retail sales]
	B51h_B51x5	Other tobacco products [Exports]
	B51h_B51x6	Other tobacco products [Imports] 165.7
	B51i_B51x1	Other tobacco products [Product]
	B51i_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B51i_B51x3	Other tobacco products [Domestic production]
	B51i_B51x4	Other tobacco products [Retail sales]
	B51i_B51x5	Other tobacco products [Exports]
	B51i_B51x6	Other tobacco products [Imports]
	B51ii_B51x1	Other tobacco products [Product]
	B51ii_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]

	B51ii_B51x3	Other tobacco products [Domestic production]
	B51ii_B51x4	Other tobacco products [Retail sales]
	B51ii_B51x5	Other tobacco products [Exports]
	B51ii_B51x6	Other tobacco products [Imports]
	B51iii_B51x1	Other tobacco products [Product]
	B51iii_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B51iii_B51x3	Other tobacco products [Domestic production]
	B51iii_B51x4	Other tobacco products [Retail sales]
	B51iii_B51x5	Other tobacco products [Exports]
	B51iii_B51x6	Other tobacco products [Imports]
	B51iiii_B51x1	Other tobacco products [Product]
	B51iiii_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B51iiii_B51x3	Other tobacco products [Domestic production]
	B51iiii_B51x4	Other tobacco products [Retail sales]
	B51iiii_B51x5	Other tobacco products [Exports]
	B51iiii_B51x6	Other tobacco products [Imports]
	B51j_B51x1	Tobacco leaves [Product]
	B51j_B51x2	Tobacco leaves [Unit (e.g. pieces, tonnes)]
	B51j_B51x3	Tobacco leaves [Domestic production]

	B51j_B51x4	Tobacco leaves [Retail sales]
	B51j_B51x5	Tobacco leaves [Exports]
	B51j_B51x6	Tobacco leaves [Imports]
B52		Please provide information on the volumes of duty-free sales (e.g. product, unit, quantity), if available. No data available
B53A		Please indicate the year of the data used to answer question B51 and 52: 2021
B53B		Please indicate the source of the data used to answer questions B51 and B52: BIR Statement of Removals and Excise Tax Collection Report (from Official Register Books) and Authority to Release Imported Goods (ATRIG) for B51
B6		Seizures of illicit tobacco products (with reference to Article 15.5)
B61a_B61x1		Seizures of illicit tobacco
	B61a_B61x1	Smoking tobacco products [Year] 2021
	B61a_B61x2	Smoking tobacco products [Product] Assorted cigarettes
	B61a_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)] Sticks
	B61a_B61x4	Smoking tobacco products [Quantity seized] 2,471,060
	B61b_B61x1	Smoking tobacco products [Year] 2020
	B61b_B61x2	Smoking tobacco products [Product] Assorted cigarettes
	B61b_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)] Sticks
	B61b_B61x4	Smoking tobacco products [Quantity seized] 3, 641, 180
	B61c_B61x1	Smoking tobacco products [Year] 2019
	B61c_B61x2	Smoking tobacco products [Product] Assorted cigarettes
	B61c_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]

		Sticks
	B61c_B61x4	Smoking tobacco products [Quantity seized] 2,852,100
	B61cc_B61x1	Smoking tobacco products [Year] 2019
	B61cc_B61x2	Smoking tobacco products [Product] Chewing tobacco
	B61cc_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)] pieces
	B61cc_B61x4	Smoking tobacco products [Quantity seized] 401,320
	B61ccc_B61x1	Smoking tobacco products [Year]
	B61ccc_B61x2	Smoking tobacco products [Product] Assorted cigarettes
	B61ccc_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)] sticks
	B61ccc_B61x4	Smoking tobacco products [Quantity seized] 35,789,170
	B61cccc_B61x 1	Smoking tobacco products [Year]
	B61cccc_B61x 2	Smoking tobacco products [Product]
	B61cccc_B61x 3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B61cccc_B61x 4	Smoking tobacco products [Quantity seized]
	B61cccc_B61 x1	Smoking tobacco products [Year]
	B61cccc_B61 x2	Smoking tobacco products [Product]
	B61cccc_B61 x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B61cccc_B61 x4	Smoking tobacco products [Quantity seized]
	B61cccc_B6 1x1	Smoking tobacco products [Year]
	B61cccc_B6 1x2	Smoking tobacco products [Product]

	B61cccc_B6 1x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B61cccc_B6 1x4	Smoking tobacco products [Quantity seized]
	B61d_B61x1	Smokeless tobacco products [Year]
	B61d_B61x2	Smokeless tobacco products [Product]
	B61d_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61d_B61x4	Smokeless tobacco products [Quantity seized]
	B61e_B61x1	Smokeless tobacco products [Year]
	B61e_B61x2	Smokeless tobacco products [Product]
	B61e_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61e_B61x4	Smokeless tobacco products [Quantity seized]
	B61f_B61x1	Smokeless tobacco products [Year]
	B61f_B61x2	Smokeless tobacco products [Product]
	B61f_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61f_B61x4	Smokeless tobacco products [Quantity seized]
	B61ff_B61x1	Smokeless tobacco products [Year]
	B61ff_B61x2	Smokeless tobacco products [Product]
	B61ff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61ff_B61x4	Smokeless tobacco products [Quantity seized]
	B61fff_B61x1	Smokeless tobacco products [Year]

	B61fff_B61x2	Smokeless tobacco products [Product]
	B61fff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61fff_B61x4	Smokeless tobacco products [Quantity seized]
	B61ffff_B61x1	Smokeless tobacco products [Year]
	B61ffff_B61x2	Smokeless tobacco products [Product]
	B61ffff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61ffff_B61x4	Smokeless tobacco products [Quantity seized]
	B61ffff_B61x1	Smokeless tobacco products [Year]
	B61ffff_B61x2	Smokeless tobacco products [Product]
	B61ffff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61ffff_B61x4	Smokeless tobacco products [Quantity seized]
	B61ffff_B61x1	Smokeless tobacco products [Year]
	B61ffff_B61x2	Smokeless tobacco products [Product]
	B61ffff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61ffff_B61x4	Smokeless tobacco products [Quantity seized]
	B61g_B61x1	Other tobacco products [Year] 2020
	B61g_B61x2	Other tobacco products [Product] Tobacco leaves
	B61g_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)] pieces
	B61g_B61x4	Other tobacco products [Quantity seized] 1,600

	B61h_B61x1	Other tobacco products [Year] 2018
	B61h_B61x2	Other tobacco products [Product] Tobacco leaves
	B61h_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)] cases
	B61h_B61x4	Other tobacco products [Quantity seized] 199
	B61i_B61x1	Other tobacco products [Year] 2018
	B61i_B61x2	Other tobacco products [Product] Tobacco leaves
	B61i_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)] Cases
	B61i_B61x4	Other tobacco products [Quantity seized] 3
	B61ii_B61x1	Other tobacco products [Year] for the other seized tobacco items please refer to: https://drive.google.com/file/d/17bZ7SDUDqt7_08zo9-sdMliQqkOGIsGW/view?usp=share_link
	B61ii_B61x2	Other tobacco products [Product]
	B61ii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61ii_B61x4	Other tobacco products [Quantity seized]
	B61iii_B61x1	Other tobacco products [Year]
	B61iii_B61x2	Other tobacco products [Product]
	B61iii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61iii_B61x4	Other tobacco products [Quantity seized]
	B61iiii_B61x1	Other tobacco products [Year]
	B61iiii_B61x2	Other tobacco products [Product]
	B61iiii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]

	B61iiii_B61x4	Other tobacco products [Quantity seized]
	B61iiii_B61x1	Other tobacco products [Year]
	B61iiii_B61x2	Other tobacco products [Product]
	B61iiii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61iiii_B61x4	Other tobacco products [Quantity seized]
	B61iiii_B61x1	Other tobacco products [Year]
	B61iiii_B61x2	Other tobacco products [Product]
	B61iiii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61iiii_B61x4	Other tobacco products [Quantity seized]
B62		<p>Do you have any information on the percentage of illicit tobacco products on the national tobacco market?</p> <p>No</p>
B63		What percentage of the national tobacco market do illicit tobacco products constitute? (%)
B64		What is the trend over the past two years or since submission of your last report in the percentage of illicit tobacco products in relation to the national tobacco market?
B65		<p>Please provide any further information on illicit tobacco products.</p> <p>The Bureau of Internal Revenue (BIR) issued Revenue Memorandum Order (RMO) No. 40-2022 prescribing the guidelines and procedures in the conduct of enforcement operations, forfeiture and prosecution of cases relative to the unlicensed/illicit/unauthorized production, importation, trade sale or possession of articles subject to excise tax.</p>
B66		<p>Please indicate the source of the data used to answer questions in section B6:</p> <p>www.bir.gov.ph</p>
B7		Tobacco-growing
B71		<p>Is there any tobacco-growing in your jurisdiction?</p> <p>Yes</p>
B72		Please provide information on the number of workers involved in tobacco-growing. If available, please provide this figure broken down by gender.
B73		Please provide, if available, the share of the value of tobacco leaf production in the national

		gross domestic product.
B74A		Please indicate the year of the data used to answer questions in section B7: 2016
B74B		Please indicate the source of the data used to answer questions in section B7: http://nta.da.gov.ph/publications_industry.html
B8		Taxation of tobacco products (with reference to Articles 6.2(a) and 6.3)
B81		What proportion of the retail price of the most popular price category of tobacco product consists of taxes (e.g. sum of excise, sales and import duties (if applicable) and value added tax/goods and services tax (VAT/GST))? In 2022, the total tax burden of the most popular cigarette brand is at 50.56% of which 39.86 percent is the share of excise tax and 10.70 percent is the share of VAT.
SQ001		How are the excise taxes levied (what types of taxes are levied)?
	SQ001	Specific tax only Yes
	SQ002	Ad valorem tax only No
	SQ003	Combination of specific and ad valorem taxes Yes
	SQ004	More complex structure (please explain below) Yes
B82a		If a more complex structure of taxes (please explain): For B83: Rates of tobacco tax, please refer to https://drive.google.com/file/d/13V8oAY9Lfty3eahXrARlynF4XJT-fYvz/view?usp=share_link
B83a_B83x1		If available, please provide details on the rates of taxation for tobacco products at all levels of Government and be as specific as possible (specify the type of tax, e.g. VAT, sales, import duties)
	B83a_B83x1	Smoking tobacco products [Product]
	B83a_B83x2	Smoking tobacco products [Type of tax]
	B83a_B83x3	Smoking tobacco products [Rate or amount]
	B83a_B83x4	Smoking tobacco products [Base of tax]
	B83b_B83x1	Smoking tobacco products [Product]
	B83b_B83x2	Smoking tobacco products [Type of tax]

	B83b_B83x3	Smoking tobacco products [Rate or amount]
	B83b_B83x4	Smoking tobacco products [Base of tax5]
	B83c_B83x1	Smoking tobacco products [Product]
	B83c_B83x2	Smoking tobacco products [Type of tax]
	B83c_B83x3	Smoking tobacco products [Rate or amount]
	B83c_B83x4	Smoking tobacco products [Base of tax5]
	B83cc_B83x1	Smoking tobacco products [Product]
	B83cc_B83x2	Smoking tobacco products [Type of tax]
	B83cc_B83x3	Smoking tobacco products [Rate or amount]
	B83cc_B83x4	Smoking tobacco products [Base of tax5]
	B83ccc_B83x1	Smoking tobacco products [Product]
	B83ccc_B83x2	Smoking tobacco products [Type of tax]
	B83ccc_B83x3	Smoking tobacco products [Rate or amount]
	B83ccc_B83x4	Smoking tobacco products [Base of tax5]
	B83cccc_B83x 1	Smoking tobacco products [Product]
	B83cccc_B83x 2	Smoking tobacco products [Type of tax]
	B83cccc_B83x 3	Smoking tobacco products [Rate or amount]
	B83cccc_B83x 4	Smoking tobacco products [Base of tax5]
	B83cccc_B83 x1	Smoking tobacco products [Product]

B83cccc_B83 x2	Smoking tobacco products [Type of tax]
B83cccc_B83 x3	Smoking tobacco products [Rate or amount]
B83cccc_B83 x4	Smoking tobacco products [Base of tax5]
B83cccc_B8 3x1	Smoking tobacco products [Product]
B83cccc_B8 3x2	Smoking tobacco products [Type of tax]
B83cccc_B8 3x3	Smoking tobacco products [Rate or amount]
B83cccc_B8 3x4	Smoking tobacco products [Base of tax5]
B83d_B83x1	Smokeless tobacco products [Product]
B83d_B83x2	Smokeless tobacco products [Type of tax]
B83d_B83x3	Smokeless tobacco products [Rate or amount]
B83d_B83x4	Smokeless tobacco products [Base of tax5]
B83e_B83x1	Smokeless tobacco products [Product]
B83e_B83x2	Smokeless tobacco products [Type of tax]
B83e_B83x3	Smokeless tobacco products [Rate or amount]
B83e_B83x4	Smokeless tobacco products [Base of tax5]
B83f_B83x1	Smokeless tobacco products [Product]
B83f_B83x2	Smokeless tobacco products [Type of tax]
B83f_B83x3	Smokeless tobacco products [Rate or amount]
B83f_B83x4	Smokeless tobacco products [Base of tax5]

	B83ff_B83x1	Smokeless tobacco products [Product]
	B83ff_B83x2	Smokeless tobacco products [Type of tax]
	B83ff_B83x3	Smokeless tobacco products [Rate or amount]
	B83ff_B83x4	Smokeless tobacco products [Base of tax5]
	B83fff_B83x1	Smokeless tobacco products [Product]
	B83fff_B83x2	Smokeless tobacco products [Type of tax]
	B83fff_B83x3	Smokeless tobacco products [Rate or amount]
	B83fff_B83x4	Smokeless tobacco products [Base of tax5]
	B83ffff_B83x1	Smokeless tobacco products [Product]
	B83ffff_B83x2	Smokeless tobacco products [Type of tax]
	B83ffff_B83x3	Smokeless tobacco products [Rate or amount]
	B83ffff_B83x4	Smokeless tobacco products [Base of tax5]
	B83fffff_B83x1	Smokeless tobacco products [Product]
	B83fffff_B83x2	Smokeless tobacco products [Type of tax]
	B83fffff_B83x3	Smokeless tobacco products [Rate or amount]
	B83fffff_B83x4	Smokeless tobacco products [Base of tax5]
	B83ffffff_B83x1	Smokeless tobacco products [Product]
	B83ffffff_B83x2	Smokeless tobacco products [Type of tax]
	B83ffffff_B83x3	Smokeless tobacco products [Rate or amount]

	B83ffff_B83x4	Smokeless tobacco products [Base of tax5]
	B83g_B83x1	Other tobacco products [Product]
	B83g_B83x2	Other tobacco products [Type of tax]
	B83g_B83x3	Other tobacco products [Rate or amount]
	B83g_B83x4	Other tobacco products [Base of tax5]
	B83h_B83x1	Other tobacco products [Product]
	B83h_B83x2	Other tobacco products [Type of tax]
	B83h_B83x3	Other tobacco products [Rate or amount]
	B83h_B83x4	Other tobacco products [Base of tax5]
	B83i_B83x1	Other tobacco products [Product]
	B83i_B83x2	Other tobacco products [Type of tax]
	B83i_B83x3	Other tobacco products [Rate or amount]
	B83i_B83x4	Other tobacco products [Base of tax5]
	B83ii_B83x1	Other tobacco products [Product]
	B83ii_B83x2	Other tobacco products [Type of tax]
	B83ii_B83x3	Other tobacco products [Rate or amount]
	B83ii_B83x4	Other tobacco products [Base of tax5]
	B83iii_B83x1	Other tobacco products [Product]
	B83iii_B83x2	Other tobacco products [Type of tax]

	B83iii_B83x3	Other tobacco products [Rate or amount]
	B83iii_B83x4	Other tobacco products [Base of tax5]
	B83iiii_B83x1	Other tobacco products [Product]
	B83iiii_B83x2	Other tobacco products [Type of tax]
	B83iiii_B83x3	Other tobacco products [Rate or amount]
	B83iiii_B83x4	Other tobacco products [Base of tax5]
	B83iiii_B83x1	Other tobacco products [Product]
	B83iiii_B83x2	Other tobacco products [Type of tax]
	B83iiii_B83x3	Other tobacco products [Rate or amount]
	B83iiii_B83x4	Other tobacco products [Base of tax5]
	B83iiii_B83x1	Other tobacco products [Product]
	B83iiii_B83x2	Other tobacco products [Type of tax]
	B83iiii_B83x3	Other tobacco products [Rate or amount]
	B83iiii_B83x4	Other tobacco products [Base of tax5]
B84		<p>Please briefly describe the trends in taxation for tobacco products in the past two years or since submission of your last report in your jurisdiction.</p> <p>Effective 01 January 2020, Republic Act (RA) No. 11346 increased the cigarette excise from Php 35.00 per pack to Php 45.00 per pack with five-peso annual increments until it reached Php 60.00 per pack in 2023. And then there will be a 5 percent annual increase in excise tax starting 2024 onwards.</p>
B85		<p>Do you earmark any percentage of your taxation income for funding any national plan or strategy on tobacco control in your jurisdiction?</p> <p>Yes</p>
B86		<p>Please provide details in the space below.</p> <p>Under RA11346, 50 percent of total excise tax collection from tobacco products shall be allocated and used exclusively in the following manner: 1) 80 percent to PhilHealth for the implementation of RA 11223 or the Universal Health Care Law. 2) 20 percent shall be allocated for medical assistance and the health enhancement facilities program (HFEP) as determined by the</p>

		Department of Health (DOH). Under RA 11346, allocation of the shares of beneficiary Local Government Units (LGU) shall be: 3) An annual amount equivalent to 5 percent of the revenues collected from excise tax on tobacco products, but not exceeding four billion pesos (PHP4,000,000.00), shall be allocated and divided among the provinces producing burley and native tobacco in accordance with the volume of tobacco leaf production, which shall be distributed as - 50 percent to the provincial government of a beneficiary province and 50 percent to beneficiary municipalities and cities of the beneficiary province, amending RA 8240. 4) An annual amount equivalent to 15 percent of the excise taxes on locally manufactured Virginia type cigarettes but not exceeding seventeen billion pesos (PHP17,000,000.00) shall be allocated to beneficiary provinces producing Virginia tobacco, notwithstanding the provision of Section 3 of Republic Act No. 7171.
B87A		Please indicate the year of the data used to answer questions B81 to B86: 2022
B87B		Please indicate the source of the data used to answer questions B81 to B86: For B81, DOF staff estimates. For B82 to B86, Republic Acts No. 10351, 10963, and 11346.
B9		Price of tobacco products (with reference to Articles 6.2(a))
1_SQ001		Domestic Please provide the retail prices of the three most widely sold brands of domestic tobacco products at the most widely used point of sale in your capital city.
	1_SQ001	Smoking tobacco products [Name of the most widely sold brand] Marlboro KS flip top box (cigarettes)
	1_SQ002	Smoking tobacco products [Number of units or amount per package] 20 sticks/pack
	1_SQ003	Smoking tobacco products [Retail price] 138.00
	1_SQ004	Smoking tobacco products [Currency] Php
	2_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	2_SQ002	Smoking tobacco products [Number of units or amount per package]
	2_SQ003	Smoking tobacco products [Retail price]
	2_SQ004	Smoking tobacco products [Currency]
	3_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	3_SQ002	Smoking tobacco products [Number of units or amount per package]
	3_SQ003	Smoking tobacco products [Retail price]
	3_SQ004	Smoking tobacco products [Currency]

	7_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	7_SQ002	Smokeless tobacco products [Number of units or amount per package]
	7_SQ003	Smokeless tobacco products [Retail price]
	7_SQ004	Smokeless tobacco products [Currency]
	8_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	8_SQ002	Smokeless tobacco products [Number of units or amount per package]
	8_SQ003	Smokeless tobacco products [Retail price]
	8_SQ004	Smokeless tobacco products [Currency]
	9_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	9_SQ002	Smokeless tobacco products [Number of units or amount per package]
	9_SQ003	Smokeless tobacco products [Retail price]
	9_SQ004	Smokeless tobacco products [Currency]
	13_SQ001	Other tobacco products [Name of the most widely sold brand] Panetelas Std. 25s (cigars)
	13_SQ002	Other tobacco products [Number of units or amount per package] 25 sticks/pack
	13_SQ003	Other tobacco products [Retail price] 429.10
	13_SQ004	Other tobacco products [Currency] Php
	14_SQ001	Other tobacco products [Name of the most widely sold brand]
	14_SQ002	Other tobacco products [Number of units or amount per package]
	14_SQ003	Other tobacco products [Retail price]

	14_SQ004	Other tobacco products [Currency]
	15_SQ001	Other tobacco products [Name of the most widely sold brand]
	15_SQ002	Other tobacco products [Number of units or amount per package]
	15_SQ003	Other tobacco products [Retail price]
	15_SQ004	Other tobacco products [Currency]
1_SQ001		Imported Please provide the retail prices of the three most widely sold brands of imported tobacco products at the most widely used point of sale in your capital city.
	1_SQ001	Smoking tobacco products [Name of the most widely sold brand] Marlboro Red and Marlboro Gold
	1_SQ002	Smoking tobacco products [Number of units or amount per package] 20 sticks/pack 152.2 Php
	1_SQ003	Smoking tobacco products [Retail price] 152.2 Php
	1_SQ004	Smoking tobacco products [Currency] php
	2_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	2_SQ002	Smoking tobacco products [Number of units or amount per package]
	2_SQ003	Smoking tobacco products [Retail price]
	2_SQ004	Smoking tobacco products [Currency]
	3_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	3_SQ002	Smoking tobacco products [Number of units or amount per package]
	3_SQ003	Smoking tobacco products [Retail price]
	3_SQ004	Smoking tobacco products [Currency]
	7_SQ001	Smokeless tobacco products [Name of the most widely sold brand]

	7_SQ002	Smokeless tobacco products [Number of units or amount per package]
	7_SQ003	Smokeless tobacco products [Retail price]
	7_SQ004	Smokeless tobacco products [Currency]
	8_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	8_SQ002	Smokeless tobacco products [Number of units or amount per package]
	8_SQ003	Smokeless tobacco products [Retail price]
	8_SQ004	Smokeless tobacco products [Currency]
	9_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	9_SQ002	Smokeless tobacco products [Number of units or amount per package]
	9_SQ003	Smokeless tobacco products [Retail price]
	9_SQ004	Smokeless tobacco products [Currency]
	13_SQ001	Other tobacco products [Name of the most widely sold brand]
	13_SQ002	Other tobacco products [Number of units or amount per package]
	13_SQ003	Other tobacco products [Retail price]
	13_SQ004	Other tobacco products [Currency]
	14_SQ001	Other tobacco products [Name of the most widely sold brand]
	14_SQ002	Other tobacco products [Number of units or amount per package]
	14_SQ003	Other tobacco products [Retail price]
	14_SQ004	Other tobacco products [Currency]

	15_SQ001	Other tobacco products [Name of the most widely sold brand]
	15_SQ002	Other tobacco products [Number of units or amount per package]
	15_SQ003	Other tobacco products [Retail price]
	15_SQ004	Other tobacco products [Currency]
B92A		Please indicate the year of the data used to answer question B91: 2022
B92B		Please indicate the source of the data used to answer question B91: Statement of removal, excise tax collection report (from official register books) and authority to release imported goods (ATRIG)
B93		Please briefly describe the trend in the prices of tobacco products in the past two years or since submission of your last report in your jurisdiction. Among adults who smoked manufactured cigarettes, the average cigarette expenditure per month (inflation-adjusted) increased from Philippine Peso (Php) 400.00 in 2009 to Php 816.20 in 2015 and then to Php 1273.90 in 2021. These correspond to relative increases of 104.1% from 2009 to 2015, 56.1% from 2015 to 2021, and 218.0% from 2009 to 2021. Likewise, the average cost of a pack of 20 manufactured cigarettes increased from Php 29.60 in 2009 to Php 57.70 in 2015 and then to Php 107.80 in 2021. The relative increases in the cost of a pack of 20 manufactured cigarettes were 94.6% from 2009 to 2015, 86.9% from 2015 to 2021, and 263.8% from 2009 to 2021. It is worth noting that tobacco products, chewing tobacco, cigars and cigarettes, prices increased as a result among others of the implementation of R.A. 11346 during the past two years.

C1. GENERAL OBLIGATIONS

C1		With reference to Article 5
C111		Have you developed and implemented comprehensive multisectoral national tobacco control strategies, plans and programmes in accordance with the Convention? Yes
C112		Have you partially developed and implemented tobacco control strategies by including tobacco control in national health, public health or health promotion strategies, plans and programmes? N/A
C113		Is any aspect of tobacco control that is referred to in the Convention included in any national strategy, plan or programme? N/A
C114a		Have you established or reinforced and financed:
	C114a	a focal point for tobacco control? Yes
	C114b	a tobacco control unit? Yes
	C114c	a national coordinating mechanism for tobacco control? Yes
C115		Please provide details (e.g. the nature of the national coordinating mechanism, the institution to which the focal point for tobacco control or the tobacco control unit belongs). To strengthen the coordinating mechanism for tobacco control within the DOH and in collaboration with its government and non-government partners, the DOH issued the Department Order No. 2022-0053: Governance Structure for the Implementation of the National Tobacco Prevention and Control Strategy.
C116		Please provide a brief description of the progress made in implementing Article 5.1 and 5.2 (General obligations) in the past two years or since submission of your last report. To continue and heighten the implementation of the national framework on tobacco control, the DOH issued and executes the following policies: 1. Administrative Order (AO) No. 2022-0046: Guidelines on Graphic Health Warnings for Vaporized Nicotine and Non-Nicotine Products and Novel Tobacco Products Pursuant to Republic Act Nos. 11900 or “Vaporized Nicotine and Non-Nicotine Regulation Act” and 10643 or “Graphic Health Warnings Law” 2. AO No. 2022-0003: National Policy on the Prevention and Control of the Use of Tobacco Products, Vapor Products, Heated Tobacco Products, and Other Novel, Emerging, or Similar Products 3. AO No. 2021-0051: Guidelines on Graphic Health Warnings on Vapor Products, Heated Tobacco Products and Other Similar Products 4. AO No. 2021-0041: Guidelines on the Implementation of Unified and Standardized Tobacco Cessation Services at All Levels of Care 5. Department Memorandum (DM) No. 2020-0156 dated March 16, 2020 on the “Submission of DOI relative to the acceptance of donations, assistance and partnerships in compliance with the CSC-DOH JMC 2010-01”
C117		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C12		Protection of public health policies with respect to tobacco control from commercial and other vested interests of the tobacco industry Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:

C121		<p>protecting public health policies with respect to tobacco control from commercial and other vested interests of the tobacco industry?</p> <p>Yes</p>
C122		<p>ensuring that the public has access, in accordance with Article 12(c), to a wide range of information on tobacco industry activities relevant to the objectives of the Convention, such as in a public repository?</p> <p>Yes</p>
C123		<p>If you answered “Yes” to any of the questions under C121 or C122, please provide details in the space below (specifically, please refer, if relevant, to whether your government or any of its departments 1) have raised awareness on tobacco industry tactics and the need to prevent interference by the tobacco industry with decision making; 2) have avoided entering into any partnerships or voluntary agreements with the tobacco industry; 3) have established any measures to limit interaction of public officials with the tobacco industry, including in the form of a code of conduct; 4) have not granted any incentives, privileges, benefits or preferential tax exemptions to the tobacco industry to establish or run their business; etc.).</p> <p>The Civil Service Commission (CSC) and the Department of Health (DOH) issued the Joint Memorandum Circular No. 2010-01: Protection of the Bureaucracy Against Tobacco Industry on June 26, 2010. Said policy covers all government officials and employees, regardless of status. It prohibits unnecessary interaction between the government and the tobacco industry except when strictly necessary for the supervision, regulation and control of the industry. To continually implement the JMC amidst the COVID-19 pandemic, the DOH issued the Department Memorandum (DM) No. 2020-0156 dated March 16, 2020 on the “Submission of DOI relative to the acceptance of donations, assistance and partnerships in compliance with the CSC-DOH JMC 2010-01” which reiterates the JMC and requires all of our donors to submit the DOI form (annex of the policy). Likewise, the DOH issued the Administrative Order No. 2021-0011 (Implementing Guidelines of Section 35 of the Universal Health Care Act, on Standards on Receipt, Assessment, and Management of Conflict of Interest) in order to provide clear and standard process in the declaration and management of COI of all persons involved in the policy-determining activities of the implementing agencies and advisory bodies/committees of the UHC. This is to ensure integrity and impartiality in decisions, and address potential graft and corruption practices. Moreover, the DOH did not accept the respirators donated by the tobacco industry given the provisions of the JMC.</p>
C124		<p>Please provide a brief description of the progress made in implementing Article 5.3 in the past two years or since submission of your last report.</p>
C125		<p>Have you utilized the “Guidelines for implementation of Article 5.3 of the WHO FCTC” when developing or implementing policies in this area?</p> <p>Yes</p>
C126		<p>Please provide details in the space below or refer to section I of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/index.php/862235?token={TOKEN}&lang=en</p>
C127		<p>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</p>

C2. MEASURES RELATING TO THE REDUCTION OF DEMAND FOR TOBACCO

C2		With reference to Articles 6–14
C21		Price and tax measures to reduce the demand for tobacco Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C211		tax policies and, where appropriate, price policies on tobacco products so as to contribute to the health objectives aimed at reducing tobacco consumption? Yes
C212		prohibiting or restricting, as appropriate, sales to international travellers of tax- and duty-free tobacco products? Yes
C213		prohibiting or restricting, as appropriate, imports by international travellers of tax- and duty-free tobacco products? Yes
C214		Please provide a brief description of the progress made in implementing Article 6 (Price and tax measures to reduce the demand for tobacco) in the past two years or since submission of your last report. Please refer to previous questions under B8 (Taxation of tobacco products)
C215		Have you utilized the “Guidelines for implementation of Article 6 of the WHO FCTC” when developing or implementing policies in this area? Yes
C216		If you answered “Yes” to question C215 please provide details in the space below or refer to section H of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en
C217		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C22		Protection from exposure to tobacco smoke Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C221		- banning, completely or partially, tobacco smoking in indoor workplaces, public transport, indoor public places and, as appropriate, other public places? Yes
1		What is the type/nature of the measure providing for the ban?
	1	national law Yes
	2	subnational law(s) Yes
	3	administrative and executive orders

		Yes
	4	voluntary agreements Yes
	5	other measures (please specify in C223 below) Yes
C223		<p>Please provide a brief explanation of the type/nature and content of the measures providing for the ban.</p> <p>Republic Act No. 9211 or the Tobacco Regulation Act of 2003 provides ban on public places and conveyances, access restriction to minors, advertising and promotions and implementation of programs and programs of the government agencies. Under Section 5 of this act, smoking shall be absolutely prohibited in the following public areas: • Center of youth activity such as playschools, preparatory schools, elementary school, high school, colleges and universities, youth hostels and recreational facilities for persons under 18 years old • Elevators and stairwells • Locations in which fire hazards are present, including gas stations and storage areas for flammable liquids, gas, explosives or combustible materials • Within the buildings and premises of public are private hospitals, medical, dental and optical clinics, health centers, nursing homes, dispensaries and laboratories • Public conveyances and public facilities including airport and ship terminals and train and bus stations, restaurants and conference halls, except for separate smoking areas; and • Food preparation areas Executive Order No. 26 signed by president Duterte in 2017 that provides for the establishment of smoke- free environments in public and enclosed places. Smoking within enclosed public places and public conveyances, whether stationary or in motion, except in fully compliant DSAs. However, no DSAs in the following public areas: • Centers of youth activity such as playschools, preparatory schools, elementary schools, high schools, colleges and universities, youth hostels and recreational facilities for minors; Elevators and stairwells • Location in which fire hazards are present, including gas stations, storage areas for flammable liquids, gas, explosives or combustible materials; • Within buildings and premises of public and private hospitals, medical, dental, and optical clinics, health centers, nursing homes, dispensaries and laboratories; and • Food preparation areas EO 26 was further strengthened by the recently passed law, the Executive Order no. 106 issued by the President in February 2020. The law prohibits vaping except in designated smoking/vaping areas. It also regulates the sale, manufacture, marketing, distribution and importation of unregistered electronic nicotine devices and other novel tobacco products. Another feature of the law is the ban of selling e-cigarettes and other tobacco products to persons aged below 21 years old. In 2022, RA 11900 lapsed into law and provides the ban of use of vaporized nicotine and non-nicotine products in the following public places: • Center of youth activity such as playschools, preparatory schools, elementary school, high school, colleges and universities, youth hostels and recreational facilities for persons under 18 years old • Elevators and stairwells • Locations in which fire hazards are present, including gas stations and storage areas for flammable liquids, gas, explosives or combustible materials • Within the buildings and premises of public are private hospitals, medical, dental and optical clinics, health centers, nursing homes, dispensaries and laboratories • Public conveyances and public facilities including airport and ship terminals and train and bus stations, restaurants and conference halls, except for separate smoking areas; and • Food preparation areas • Churches and other similar places where people congregate for worship • Within the buildings of government offices except for DVAs However, the said new law also transferred regulatory jurisdiction over these products from the FDA to the DTI. Further, the law reduced the minimum age for purchase and sale of these products from 21 to 18 years of age. Sub-national laws include ordinances issued by provinces, cities or municipalities. These are drafted by the local legislative council and implemented at localities administered either by the Provincial Governors, City/ Municipal Mayors and Barangay Captains. Local laws on tobacco control may be more stringent than the national law in view of the autonomy provided to local government units by the Local Government Code of 1991. It is worth noting that in the national capital region, there are seventeen (17) local government units that have local ordinances regulating tobacco use.</p>
C224		<p>Do any of these measures provide for a mechanism/ infrastructure for enforcement?</p> <p>Yes</p>
C225		<p>Please provide details of this system.</p> <p>Section 29 of Republic Act 9211 provides the Inter-Agency Committee on Tobacco the power to administer and implement provisions of the law. The Committee is headed by the Department of Trade and Industry (DTI) as Chairperson and co-chaired by the Department of Health (DOH). Members include the Department of Agriculture, Department of Justice, Department of Environment and Natural Resources, Department of Science and Technology, Department of Education, National Tobacco Administration, representative from the Tobacco Industry and a Non-Government Organization. The Monitoring and Enforcement Guidelines (MEG) of RA 9211 details the designation and functions of pilot agencies in the implementation of the law as well as the</p>

		<p>procedures in the filing of complaints, investigation, and reporting. Violations have corresponding penalties under the law. For vaporized nicotine and non-nicotine products, pursuant to Section 21 or RA 11900, the Department of Trade and Industry (DTI) is designated to have exclusive jurisdiction over any and all issues, requirements, and subject matters related to vaporized nicotine and non-nicotine products and novel tobacco products and their devices. At the sub-national level, pursuant to Executive Order Nos. 26, s. 2017 and 106, s. 2020, the Local Government Units (LGUs) may assign or deputize a specific task force (otherwise known as smoke-free task forces) to enforce the ordinance on tobacco control. The composition of the task force differs from each LGU, and may include but not be limited to the City/ Municipal Departments such as the City/ Municipal Health Office or City/ Municipal Environment and Natural Resources Office, the Local Police Force, Sanitary Inspectors or Traffic Enforcers. Local Tobacco Control Councils may be created to serve as the implementation arm of the LGU. Most of the local enforcers at the sub-national level are authorized to issue citation tickets for violation of their local ordinances. Similarly, violations have corresponding penalties. Based on the said law, Metro Manila LGUs have established Local Tobacco Control Councils and trained enforcers from various departments such as in Health, Environmental and Natural Resources, Public Order and Safety, and Business Permit and Licensing Office.</p>
1		<p>Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Indoor workplaces:</p>
	1	<p>government buildings</p> <p>Complete</p>
	2	<p>health-care facilities</p> <p>Complete</p>
	3	<p>educational facilities⁶</p> <p>Complete</p>
	4	<p>universities</p> <p>Complete</p>
	5	<p>private workplaces</p> <p>Partial</p>
	6	<p>other (please specify below)</p> <p>Complete</p>
C226aa		<p>Please provide a brief explanation of any "other" policies in the space below</p> <p>Religious institutions, public transport and conveyances</p>
1		<p>Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Public transport:</p>
	1	<p>airplanes</p> <p>Complete</p>
	2	<p>trains</p> <p>Complete</p>
	3	<p>ferries</p> <p>Partial</p>
	4	<p>ground public transport (buses, trolleybuses, trams)</p> <p>Complete</p>
	5	<p>private vehicles</p>

		None
	6	other (please specify below) Complete
C226bb		Please provide a brief explanation of any "other" policies in the space below The policies developed by the Office of the President, Civil Service Commission (CSC), Land Transportation Franchising and Regulatory Board (LTFRB), Department of Education (DEPED), Commission on Higher Education (CHED), and the Department of Health (DOH) supported smoke-free environments in government offices, public transportation, schools, universities, health care facilities, and other public places.
1		Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Indoor public places:
	1	cultural facilities Partial
	2	shopping malls Partial
	3	pubs and bars Partial
	4	nightclubs Partial
	5	restaurants Partial
	7	other (please specify below)
C226cc		Please provide a brief explanation of any "other" policies in the space below
C227		Please provide a brief summary of complete and partial measures, with specific details of the partial measures that have been implemented:
C227a		Banning tobacco smoking in indoor workplaces Smoking is prohibited in all public places including private workplaces except for fully compliant DSAs. The CSC Memorandum Circular No. 17 s. 2009 prohibits smoking based on 100% smoke free environment policy of the WHO FCTC Article 8 and its guidelines. This applies in or on the premises, buildings, and grounds of government agencies providing health, education and or social welfare and development services such as hospitals, schools, colleges and universities and among others.
C227b		Banning tobacco smoking in public transport Smoking is prohibited in all public conveyances whether stationary or in motion, except for fully compliant DSAs. Effective January 7, 2010 of the LTFRB Memorandum Circular No. 2009-036 requires all holders of certificates of public convenience, to observe the smoking prohibition in all public utility vehicles and public land transportation terminals as well as to prominently post no smoking signage in their authorized units and premises in accordance with the memorandum circular. Penalties for non-compliance are subject to the provision of the said order. In some LGUs in Metro Manila, transport terminals are absolute smoke-free based on local ordinances. It is noted that exposure to secondhand smoke in homes and various public places significantly declined. The exposure to secondhand smoke in public transportation declined from 55.3% in 2009 to 37.6% in 2015 and then to 12.2% in 2021.

C227c		<p>Banning tobacco smoking in indoor public places</p> <p>-Government offices, public and private elementary and high schools, colleges and universities imposes absolute smoking ban. Policies that supported the prohibition of smoking in indoor public places include Department of Education Department Order No. 48, s. 2016 entitled "Policy and Guidelines On Comprehensive Tobacco Control" and CHED Memorandum Order no. 63 s. 2007 Prohibition of Smoking in Higher Education Institutions. -Private institutions may have designated smoking areas or may impose stricter measures in their buildings or establishments to better ensure smoke-free environment in their premises. -All enclosed public places not considered as absolute smoke-free, may or may not establish designated smoking area. In Metro Manila, some LGUs allow DSA in open spaces while some in enclosed separate rooms following strict requirements.</p>
C228		<p>Please provide a brief description of the progress made in implementing Article 8 (Protection from exposure to tobacco smoke) in the past two years or since submission of your last report.</p> <p>In 2021, the Department of Health started to conduct pilot testing of the Smoke-free and Vape-free Community Playbook, which provides local government units with ready-to-use tools to help promote and protect a critical determinant of health and well-being: preventing dangerous and harmful substance abuse, like smoking, among vulnerable populations. At the sub-national level, there is an increasing number of Local Government Units with local ordinances on 100% smoke free environments through continued technical assistance and advocacy campaigns. Efforts are being made to ensure that local ordinances are consistent with FCTC provisions. Moreover, it is worth noting that exposure to secondhand smoke in homes and various public places significantly declined. The exposure at home declined from 54.4% in 2009 to 34.7% in 2015 and 21.8% in 2021. The exposure to secondhand smoke in public transportation declined from 55.3% in 2009 to 37.6% in 2015 and then to 12.2% in 2021.</p>
C229		<p>Have you utilized the "Guidelines for implementation of Article 8 of the WHO FCTC" when developing or implementing policies in this area?</p> <p>Yes</p>
C2210		<p>If you answered "Yes" to question C229 please provide details in the space below or refer to section B of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en</p>
C2211		<p>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</p>
C23		<p>Regulation of the contents of tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</p>
C231		<p>testing and measuring the contents of tobacco products?</p> <p>Yes</p>
C232		<p>testing and measuring the emissions of tobacco products?</p> <p>Yes</p>
C233		<p>regulating the contents of tobacco products?</p> <p>N/A</p>
C234		<p>regulating the emissions of tobacco products?</p> <p>Yes</p>
C235		<p>Please provide a brief description of the progress made in implementing Article 9 (Regulation of the contents of tobacco products) in the past two years or since submission of your last report.</p> <p>(no data provided from items C231 to C245)</p>

C236		<p>Have you utilized the “Guidelines for implementation of Articles 9 and 10 of the WHO FCTC” when developing or implementing policies in this area?</p> <p>Yes</p>
C237		<p>If you answered “Yes” to question C236 please provide details in the space below or refer to section C of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en</p>
C238		<p>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g., whether your country 1) has incorporated product regulation in the national tobacco control legislation; 2) has access to either governmental or independent – not owned or controlled by the tobacco industry – laboratories for testing contents and/or emissions of tobacco products; 3) has regulated ingredients, such as flavours (e.g. menthol); 4) has regulated product characteristics, such as design features (e.g., cigarette ventilation); etc.).</p>
C24		<p>Regulation of tobacco product disclosures Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</p>
1		<p>requiring manufacturers or importers of tobacco products to disclose to Government authorities information about the:</p>
	1	<p>contents of tobacco products?</p> <p>Yes</p>
	2	<p>emissions of tobacco products?</p> <p>Yes</p>
1		<p>requiring public disclosure of information about the:</p>
	1	<p>contents of tobacco products?</p> <p>Yes</p>
	2	<p>emissions of tobacco products?</p> <p>Yes</p>
C243		<p>Please provide a brief description of the progress made in implementing Article 10 (Regulation of tobacco product disclosures) in the past two years or since submission of your last report.</p> <p>(no data provided from C241 to C245)</p>
C244		<p>Have you utilized the “Guidelines for implementation of Articles 9 and 10 of the WHO FCTC” when developing or implementing policies in this area?</p> <p>Yes</p>
C245		<p>If you answered “Yes” to question C244 please provide details in the space below or refer to section C of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en</p>
C246		<p>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g. whether your country has incorporated tobacco product disclosures in the national tobacco control legislation; has regulated the public disclosure of toxic constituents and emissions of tobacco products, aiming to raise</p>

		<p>public awareness and advance tobacco control policy; etc.).</p> <p>In July 2021, the Supreme Court issued a decision under GR No. 200431 which upheld the Food and Drug Administration's authority over the health aspect of tobacco products pursuant to Republic Act No. 9711. The FDA received a copy of the decision in June 2022 and had initiated its preparation for the development of its regulatory framework, including the implementation of Articles 9 and 10 of the WHO-FCTC.</p>
C25		<p>Packaging and labelling of tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</p>
C251		<p>requiring that packaging, individual cigarettes or other tobacco products do not carry advertising or promotion?</p> <p>Yes</p>
C252		<p>requiring that packaging and labelling do not promote a product by any means that are false, misleading, deceptive or likely to create an erroneous impression about its characteristics, health effects, hazards or emissions?</p> <p>Yes</p>
C253		<p>requiring that each unit packet and package of tobacco products and any outside packaging and labelling of such products carry health warnings describing the harmful effects of tobacco use?</p> <p>Yes</p>
C254		<p>ensuring that the health warnings are approved by the competent national authority?</p> <p>Yes</p>
C255		<p>ensuring that the health warnings are rotated?</p> <p>Yes</p>
C256		<p>ensuring that the health warnings are clear, visible and legible?</p> <p>Yes</p>
C257		<p>Does your law mandate, as a minimum, a style, size and colour of font to render the warning clear, visible and legible?</p> <p>Yes</p>
C258		<p>ensuring that the health warnings occupy no less than 30% of the principal display areas?</p> <p>Yes</p>
C259		<p>ensuring that the health warnings occupy 50% or more of the principal display areas?</p> <p>Yes</p>
C2510		<p>ensuring that health warnings are in the form of, or include, pictures or pictograms?</p> <p>Yes</p>
C2511		<p>Does the Government own the copyright to these pictures and pictograms?</p> <p>No</p>
C2512		<p>Would you grant a non-exclusive and royalty-free licence for the use of health warnings developed in your jurisdiction with other Parties?</p> <p>Yes</p>
1		<p>requiring that each unit packet and package of tobacco products and any outside packaging and labelling of such products contain information on relevant:</p>
	1	<p>constituents of tobacco products?</p>

		No
	2	emissions of tobacco products? No
C2514		requiring that the warnings and other textual information appear on each unit packet and package and on any outside packaging and labelling in the principal language or languages of the country? Yes
C2515		Please provide a brief description of the progress made in implementing Article 11 (Packaging and labelling of tobacco products) in the past two years or since submission of your last report. Recent laws have provided the Department of Health with the development and issuance of guidelines on graphic health warnings for vapor products, heated tobacco products, and other tobacco products. Aside from the guidelines, the DOH has also released updated templates for the aforementioned products as well as for tobacco products, pursuant to the GHW Law. This year, the DOH is set to release the 5th set of GHW templates for tobacco products. The 1st set of GHW templates for vapor products, heated tobacco products, and novel tobacco products was issued last year (2022), pursuant to the new Vape Law.
C2516		Have you utilized the “Guidelines for implementation of Article 11 of the WHO FCTC” when developing or implementing policies in this area? Yes
C2517		If you answered “Yes” to question C2516 please provide details in the space below or refer to section D of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en
C2518		If you have any other relevant information pertaining to or not covered in this section, please provide details in the space below.
C26		Education, communication, training and public awareness Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C261		educational and public awareness programmes? (Please refer to programmes implemented since submission of your two-year report.) Yes
1		To whom are these programmes targeted?
	1	adults or the general public Yes
	2	children and young people Yes
	3	men Yes
	4	women Yes
	5	pregnant women

		Yes
	6	ethnic groups No
	7	other Yes
C2621		Please specify PUV Drivers (MMDA), government officials and employees, local chief executives, commuters, social media users, faith based group
1		Do you reflect the following key differences among targeted population groups in educational and public awareness programmes?
	1	age Yes
	2	gender Yes
	3	educational background No
	4	cultural background No
	5	socioeconomic status No
	6	other No
C2631		Please specify
1		Do these educational and public awareness programmes cover:
	1	health risks of tobacco consumption? Yes
	2	health risks of exposure to tobacco smoke? Yes
	3	benefits of the cessation of tobacco use and tobacco-free lifestyles? Yes
	4	adverse economic consequences of tobacco production? No
	5	adverse economic consequences of tobacco consumption? Yes
	6	adverse environmental consequences of tobacco production? Yes

	7	adverse environmental consequences of tobacco consumption? Yes
1		awareness and participation of the following agencies and organizations in development and implementation of intersectoral programmes and strategies for tobacco control:
	1	public agencies? Yes
	2	nongovernmental organizations not affiliated with the tobacco industry? Yes
	3	private organizations? Yes
	4	other No
C2651		Please specify
C266		Are the elaboration, management and implementation of communication, education, training and public awareness programmes guided by research and do they undergo pre-testing, monitoring and evaluation? Yes
1		Are appropriate and special training or sensitization and awareness programmes on tobacco control addressed to:
	1	health workers? Yes
	2	community workers? Yes
	3	social workers? Yes
	4	media professionals? Yes
	5	educators? Yes
	6	decision-makers? Yes
	7	administrators? Yes
	8	other Yes
C2671		Please specify

C268		<p>Please provide a brief description of the progress made in implementing Article 12 (Education, communication, training and public awareness) in the past two years or since submission of your last report.</p> <p>The DOH-Health Promotion Bureau has issued the National Policy on Tobacco Prevention and Control, which serves as the strategic framework to guide the health sector in tobacco prevention and control. The National Tobacco Prevention and Control Strategy 2030 shall be issued within the year. In partnership with Civil Society Organizations, the DOH has developed a legal training manual which shall be used to capacitate national government agencies, local government units, and any other relevant stakeholders that may be subject to legal challenges by the tobacco/nicotine industry. Furthermore, the DOH and CSOs continually hold coordination meetings for strategic communication planning for tobacco awareness. Every year, the DOH leads the kick off activity for the annual observance of World No Tobacco Day and National No Smoking Month, convening different agencies and sectors of society in carrying out tobacco control measures. On the subnational level, LGUs implement communication plan for tobacco control. The Red Orchid Awards for 100% Tobacco-Free Environments by the Department of Health further enhanced the implementation of the ordinances. Republic Act No. 10643 mandated the issuance of three sets of templates of graphic health warnings on cigarette packages. The Department of Health developed a national coordinating mechanism to work with different government agencies, civil society, and specialty organizations to implement key articles of the FCTC. The policies on protection of the bureaucracy against tobacco industry interference guided the government agencies in developing and enforcing relevant policies using standards set by the FCTC.</p>
C269		<p>Have you utilized the “Guidelines for implementation of Article 12 of the WHO FCTC” when developing and implementing policies in this area?</p> <p>Yes</p>
C2610		<p>If you answered “Yes” to question C269 please provide details in the space below or refer to section E of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en</p>
C2611		<p>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</p>
C27		<p>Tobacco advertising, promotion and sponsorship Have you adopted and implemented, where appropriate, any legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes:</p>
C271		<p>instituting a comprehensive ban on all tobacco advertising, promotion and sponsorship?</p> <p>No</p>
1		<p>Does your ban cover:</p>
	1	<p>display and visibility of tobacco products at points of sales?</p> <p>N/A</p>
	2	<p>the domestic Internet?</p> <p>N/A</p>
	3	<p>the global Internet?</p> <p>N/A</p>
	4	<p>brand stretching and/or brand sharing?</p> <p>N/A</p>
	5	<p>product placement as a means of advertising or promotion?</p> <p>N/A</p>
	6	<p>the depiction of tobacco or tobacco use in entertainment media products?</p>

		N/A
	7	tobacco sponsorship of international events or activities and/or participants therein? N/A
	8	contributions from tobacco companies to any other entity for “socially responsible causes” and/or any other activities implemented under the umbrella of “corporate social responsibility” by the tobacco industry? N/A
	9	cross-border advertising, promotion and sponsorship originating from your territory? N/A
	10	the same forms of cross-border advertising, promotion and sponsorship entering your territory for which domestic regulation apply? N/A
C273		are you precluded by your constitution or constitutional principles from undertaking a comprehensive ban on tobacco advertising, promotion and sponsorship? No
C274		applying restrictions on all tobacco advertising, promotion and sponsorship? Yes
C275		applying restrictions on cross-border advertising, promotion and sponsorship originating from your territory with cross-border effects? No
C276		prohibiting those forms of tobacco advertising, promotion and sponsorship that promote a tobacco product by any means that are false, misleading, deceptive or likely to create an erroneous impression about its characteristics, health effects, hazards or emissions? No
C277		requiring that health or other appropriate warnings or messages accompany all tobacco advertising, promotion and sponsorship? Yes
C278		restricting the use of direct or indirect incentives that encourage the purchase of tobacco products by the public? Yes
C279		requiring the disclosure to relevant Government authorities of expenditures by the tobacco industry on advertising, promotion and sponsorship not yet prohibited? No
1		restricting tobacco advertising, promotion and sponsorship on:
	1	radio? Yes
	2	television? Yes
	3	print media? Yes
	4	the domestic Internet?

		No
	5	the global Internet? No
	6	other media? Yes
C27101		Please specify Other: outdoor media
1		restricting tobacco sponsorship of:
	1	international events and activities? Yes
	2	participants therein? Yes
C2712		cooperating with other Parties in the development of technologies and other means necessary to facilitate the elimination of cross-border advertising? Yes
C2713		imposing penalties for cross-border advertising equal to those applicable to domestic advertising, promotion and sponsorship originating from your territory in accordance with national law? No
C2714		Please provide a brief description of the progress made in implementing Article 13 (Tobacco advertising, promotion and sponsorship) in the past two years or since submission of your last report. Under RA 9211, TAPS is restricted in national media and outdoor advertisements however it does not preclude a comprehensive ban on TAPS. Provision on comprehensive TAPS ban was included in the proposed amendments of RA 9211, however, there is no development yet due to competing priorities on legislative agenda. To address this issue, some local government units issued their own policies banning TAPS at their level. Exposure to any cigarette advertising, promotion, and sponsorship in the past 30 days decreased significantly from 74.3% in 2009 to 58.6% in 2015 and then to 46.7% in 2021. Similarly, in-store cigarette advertising or promotion decreased significantly from 57.6% in 2009 to 44.0% in 2015 and then to 35.2% in 2021.
C2715		Have you utilized the “Guidelines for implementation of Article 13 of the WHO FCTC” when developing and implementing policies in this area? Yes
C2716		If you answered “Yes” to question C2715 please provide details in the space below or refer to section F of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en
C2717		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C28		Demand reduction measures concerning tobacco dependence and cessation Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C281		developing and disseminating appropriate, comprehensive and integrated guidelines based

		on scientific evidence and best practices? Yes
1		programmes to promote cessation of tobacco use, including:
	1	media campaigns emphasizing the importance of quitting? Yes
	2	programmes specially designed for underage girls and young women? No
	3	programmes specially designed for women? No
	4	programmes specially designed for pregnant women? No
	5	telephone quitlines? Yes
	6	local events, such as activities related to World No Tobacco Day or National No Smoking Day, if appropriate? Yes
	7	other? Yes
C2821		Please specify other: LGU level promotion
1		design and implementation of programmes aimed at promoting the cessation of tobacco use, in such locations as:
	1	educational institutions? Yes
	2	health-care facilities? Yes
	3	workplaces? Yes
	4	sporting environments? Yes
	5	other? Yes
C2831		Please specify
1		inclusion of diagnosis and treatment of tobacco dependence and counselling services for cessation of tobacco use in national programmes, plans and strategies for:
	1	tobacco control?

		Yes
	2	health? Yes
	3	education? Yes
C285		inclusion of programmes on the diagnosis and treatment of tobacco dependence in your health-care system? Yes
1		Which structures in your health-care system provide programmes for the diagnosis and treatment of tobacco dependence?
	1	primary health care Yes
	2	secondary and tertiary health care Yes
	3	specialist health-care systems (please specify below) Yes
	4	specialized centres for cessation counselling and treatment of tobacco dependence Yes
	5	rehabilitation centres Yes
1		Are the services provided in these settings covered by public funding or reimbursement schemes?
	1	primary health care Fully
	2	secondary and tertiary health care Partially
	3	specialist health-care systems (please specify below) Partially
	4	specialized centres for cessation counselling and treatment of tobacco dependence Partially
	5	rehabilitation centres None
	6	other (please specify below) None
C287b		Please provide other details in the space below.
1		Which health and other professionals are involved in programmes offering treatment for tobacco dependence and counselling services? Health professionals including:

	1	physicians Yes
	2	dentists Yes
	3	family doctors Yes
	4	practitioners of traditional medicine No
	5	other medical professionals (please specify below) No
	6	nurses Yes
	7	midwives Yes
	8	pharmacists Yes
	9	Community workers Yes
	10	Social workers Yes
	11	other (please specify) Yes
1		training on tobacco dependence treatment incorporated into the curricula of health professional training at pre- and post-qualification levels at the following schools:
	1	medical? Yes
	2	dental? No
	3	nursing? No
	4	pharmacy? Yes
C2810		facilitating accessibility and/or affordability of pharmaceutical products for the treatment of tobacco dependence? Yes
C2811		Where and how can these products be legally purchased in your country? Drugs/Medicines such as NRTs (in pastilles, gums and patch) and varenicline are already included

		in the 2017 Philippine National Formulary 8th Edition, hence government agencies and local government units may procure these products for their constituents. Some products are classified as over the counter medicines. As of May 20, 2021, DOH signed the request for inclusion of NRTs and Varenicline in the Primary Formulary Care which is reflected in the DM 2021-0242: or the Inclusion of Nicotine Replacement Therapy and Varenicline in the Primary Care Formulary.
1		Which pharmaceutical products are legally available for the treatment of tobacco dependence in your jurisdiction?
	1	nicotine replacement therapy Yes
	2	bupropion Yes
	3	varenicline Yes
	4	other (please specify) No
1		Are the costs of these products covered by public funding or reimbursement?
	1	nicotine replacement therapy None
	2	bupropion None
	3	varenicline None
	4	other (please specify below) None
C2813b		Please provide other details in the space below.
C2814		Please provide a brief description of the progress made in implementing Article 14 (Demand reduction measures concerning tobacco dependence and cessation) in the past two years or since submission of your last report. The DOH has issued the guidelines on the implementation of standardized and unified tobacco cessation services at different levels of care. Currently, capacity development activities are currently being conducted by the DOH for tobacco program managers at the subnational level. With the passing of the Universal Health Care Act, the government shall expand its existing benefit packages and establish financing mechanisms for the provision of basic primary care services including BTI. DOH is lobbying to Philhealth to include pharmacologic treatment for tobacco dependence in its benefit packages. Tobacco cessation services are incorporated in the Omnibus Health Guidelines per lifestage (AO 2022-0018).
C2815		Have you utilized the “Guidelines for implementation of Article 14 of the WHO FCTC” when developing and implementing policies in this area? Yes
C2816		Please provide details in the space below or refer to section G of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en

C2817	<p>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</p> <p>-AO No. 2011-003 dated April 14, 2011: National Policy on Strengthening the Prevention and Control of Chronic Lifestyle-Related Diseases -AO No. 2021-0031 dated April 5 2021: Guidelines on the Implementation of Unified and Standardized Tobacco Cessation Services at All Level of Care -AO No. 2022-0018 dated June 30 2022: Development and Utilization of the Omnibus Health Guidelines per Lifestage</p>
-------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

C3. MEASURES RELATING TO THE REDUCTION OF THE SUPPLY OF TOBACCO

C3		With reference to Articles 15–17
C31		Illicit trade in tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C311		requiring marking of all unit packets and packages of tobacco products and any outside packaging of such products to assist in determining the origin of the product? Yes
C312		requiring marking of all unit packets and packages of tobacco products and any outside packaging of such products to assist in determining whether the product is legally sold on the domestic market? Yes
C313		requiring that unit packets and packages of tobacco products for retail and wholesale use that are sold on the domestic market carry the statement: “Sales only allowed in ...” or carry any other effective marking indicating the final destination of the product? Yes
C314		developing a practical tracking and tracing regime that would further secure the distribution system and assist in the investigation of illicit trade? Yes
C315		requiring that marking is presented in legible form and/or appears in the principal language or languages of the country? Yes
C316		requiring the monitoring and collection of data on cross-border trade in tobacco products, including illicit trade? Yes
C317		facilitating the exchange of this information among customs, tax and other authorities, as appropriate, and in accordance with national law and applicable bilateral and multilateral agreements? No
C318		enacting or strengthening legislation, with appropriate penalties and remedies, against illicit trade in tobacco products, including counterfeit and contraband cigarettes? Yes
C319		requiring that confiscated manufacturing equipment, counterfeit and contraband cigarettes and other tobacco products derived from illicit trade are destroyed, using environment-friendly methods where possible, or disposed of in accordance with national law? Yes
C3110		adopting and implementing measures to monitor, document and control the storage and distribution of tobacco products held or moving under suspension of taxes or duties? Yes
C3111		enabling the confiscation of proceeds derived from illicit trade in tobacco products? Yes
C3112		promoting cooperation between national agencies and relevant regional and international intergovernmental organizations in investigations, prosecutions and proceedings, with a view to eliminating illicit trade in tobacco products, with special emphasis on cooperation at regional and subregional levels?

		Yes
C3113		licensing or other actions to control or regulate production and distribution in order to prevent illicit trade? Yes
C3114		Please provide a brief description of the progress made in implementing Article 15 (Illicit trade in tobacco products) in the past two years or since submission of your last report.
C3115		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C32		Sales to and by minors Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C321		prohibiting the sales of tobacco products to minors? Yes
C321a		Please specify the legal age: 18
C322		requiring that all sellers of tobacco products place a clear and prominent indicator inside their point of sale about the prohibition of tobacco sales to minors? Yes
C323		requiring that, in case of doubt, each seller of tobacco products requests that the purchaser provides appropriate evidence of having reached full legal age? Yes
C324		banning the sale of tobacco products in any manner by which they are directly accessible, such as open store shelves? No
C325		prohibiting the manufacture and sale of sweets, snacks, toys or any other objects in the form of tobacco products which appeal to minors? Yes
C326		prohibiting the sale of tobacco products from vending machines? No
C327		Do you ensure that tobacco vending machines are not accessible to minors and/or do not promote the sale of tobacco products to minors? No
1		prohibiting and/or promoting the prohibition of the distribution of free tobacco products:
	1	to the public? No
	2	to minors? Yes
C329		prohibiting the sale of cigarettes individually or in small packets?

		No
C3210		providing for penalties against sellers and distributors in order to ensure compliance? Yes
C3211		prohibiting the sales of tobacco products by minors? Yes
C3212		Please provide a brief description of the progress made in implementing Article 16 (Sales to and by minors) in the past two years or since submission of your last report. The Bureau of Internal Revenue (BIR) issued Revenue Regulations No 7-2021 in compliance with Republic Act No. 10643, otherwise known as “An Act to Effectively Instill Health Consciousness Through Graphic Health Warnings on Tobacco Products” and Joint Memorandum Circular No. 3-2020 which directs the printing of legal age for smoking in the containers/packs of tobacco products. On the subnational level, some local government units have issued laws/policies prohibiting the sales of small packets. Likewise under the national law, schools must have posters that sale of cigarette products is prohibited within 100 meters.
C3213		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C33		Provision of support for economically viable alternative activities Have you adopted and implemented, where appropriate, measures or programmes on any of the following:
1		promoting economically viable and sustainable alternatives for:
	1	tobacco growers? Yes
	2	tobacco workers? Yes
	3	tobacco individual sellers? No
C332		Please provide a brief description of the progress made in implementing Article 17 (Provision of support for economically viable alternative activities) in the past two years or since submission of your last report.
C333		Have you utilized the “Policy options and recommendations on economically sustainable alternatives to tobacco growing (in relation to Articles 17 and 18 of the WHO FCTC)” when developing and implementing policies in this area? Yes
C334		Please provide details in the space below or refer to section I of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en
C335		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.

C4. OTHER MEASURES AND POLICIES

C4		With reference to Articles 18–21
C41		Protection of the environment and the health of persons Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
1		implementing measures in respect of tobacco cultivation within your territory, which take into consideration:
	1	the protection of the environment? Yes
	2	the health of persons in relation to the environment? Yes
1		implementing measures in respect of tobacco manufacturing within your territory, which take into consideration:
	1	the protection of the environment? No
	2	the health of persons in relation to the environment? No
C413		Please provide a brief description of the progress made in implementing Article 18 (Protection of the environment and the health of persons) in the past two years or since submission of your last report.
C414		Have you utilized the “Policy options and recommendations on economically sustainable alternatives to tobacco growing (in relation to Articles 17 and 18 of the WHO FCTC)” when developing and implementing policies in this area? Yes
C415		If you answered “Yes” to question C414 please provide details in the space below or refer to section I of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en
C416		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C42		Liability Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
SQ001		Does your tobacco control legislation contain measures regarding criminal liability for any violations of that tobacco control legislation?
	SQ001	

		Yes
SQ001		Do you have separate criminal liability provisions in relation to tobacco control (outside of the tobacco control legislation)?
	SQ001	No
SQ001		Do you have any civil liability measures that are specific to tobacco control?
	SQ001	No
SQ001		Do you have any general civil liability provisions that could apply to tobacco control?
	SQ001	No
SQ001		Do you have civil or criminal liability provisions that provide for compensation for adverse health effects and/or for reimbursement of medical, social or other relevant costs?
	SQ001	No
SQ001		?Has any person in your jurisdiction launched any criminal and/or civil liability action, including compensation where appropriate, against any tobacco company in relation to any adverse health effect caused by tobacco use?
	SQ001	Not applicable
SQ001		Have you taken, as appropriate, any legislative, executive, administrative and/or other action against the tobacco industry for full or partial reimbursement of medical, social and other relevant costs related to tobacco use in your jurisdiction?
	SQ001	Not applicable
C428		Please provide a brief description of any progress made, as appropriate, in implementing Article 19 (Liability) in the past two years or since submission of your last report.
C429		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below. Executive Order No. 106, Section 11. Expansion of Mandate of the Smoke-Free Task Force. Section 9 of E.O. No. 26 is likewise amended as follows: Section 9. Smoke/Vape-Free Task Force. All cities and municipalities are enjoined to form a local Smoke/Vape-Free Task Force to help carry out the provisions of this Order. Members of the Philippine National Police and Smoke/Vape-Free Task Forces are directed to carry out the provisions of this Order, including the apprehension of violators and the institution of criminal proceedings for violations of this Order, in accordance with relevant laws, rules and regulations, and strictly observing due process.
C43		Research, surveillance and exchange of information Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:

1		developing and/or promoting research that addresses:
	1	determinants of tobacco consumption? No
	2	consequences of tobacco consumption? Yes
	3	social and economic indicators related to tobacco consumption? Yes
	4	tobacco use among women, with special regard to pregnant women? No
	5	the determinants and consequences of exposure to tobacco smoke? Yes
	6	identification of effective programmes for the treatment of tobacco dependence? No
	7	identification of alternative livelihoods? No
C4311		Please specify GHW compliance, Economic burden, Policy compliance study, Capacity Development for field officers (collaboration between government and CSOs)
C432		training and support for all persons engaged in tobacco control activities, including research, implementation and evaluation? Yes
1		a national system for epidemiological surveillance of:
	1	patterns of tobacco consumption? Yes
	2	determinants of tobacco consumption? Yes
	3	consequences of tobacco consumption? Yes
	4	social, economic and health indicators related to tobacco consumption? Yes
	5	exposure to tobacco smoke? Yes
C4331		Please specify Sin Tax Annual Report of the Department of Health (2020, 2021, 2022)
C434		Please list all surveys, including the year of the survey, that you have undertaken in the past.

		-Global Adult Tobacco Survey (GATS) -Global Youth Tobacco Survey (GYTS) -Compliance Study on Enforcement of Smoke-Free Environment Policy in Metropolitan Manila (January 2020) - Compliance Study on Enforcement of Smoke-Free Environment Policy in Navotas City, 2021
C435		<p>Does your country have any plans to repeat any of the above or to undertake a new tobacco survey within three to five years of your last survey? Please provide details in the space below.</p> <p>-GATS was conducted in 2021; its results were disseminated in 2022. -GYTS will be conducted in 2023. -The Metropolitan Manila Development Authority (MMDA) is targeting 2 LGUs in Metro Manila to conduct compliance study in collaboration with their local academe</p>
1		regional and global exchange of publicly available national:
	1	<p>scientific, technical, socioeconomic, commercial and legal information?</p> <p>Yes</p>
	2	<p>information on the practices of the tobacco industry?</p> <p>Yes</p>
	3	<p>information on the cultivation of tobacco?</p> <p>Yes</p>
1		an updated database of:
	1	<p>laws and regulations on tobacco control?</p> <p>Yes</p>
	2	<p>information about the enforcement of laws on tobacco control?</p> <p>Yes</p>
	3	<p>pertinent jurisprudence?</p> <p>Yes</p>
C438		<p>Please provide a brief description of the progress made in implementing Article 20 (Research, surveillance and exchange of information) in the past two years or since submission of your last report.</p> <p>The 3rd version of the GATS was disseminated in 2022. In terms of research, there have been studies on graphic health warnings and plain packaging. There are ongoing research on economic burden of tobacco and GHW compliance studies. In the near future, research will be undertaken to provide evidence for taxation, illicit trade, and health effects of emerging novel tobacco products.</p>
C439		<p>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g. whether you included information on WHO FCTC implementation in your Voluntary National Review (VNR) on the Sustainable Development Goals (SDGs), related to target 3.a).</p>

D. INTERNATIONAL COOPERATION AND ASSISTANCE

D0		Pursuant to Article 21.1(c) and in accordance with Article 26, have you either provided or received financial or technical assistance (be it through unilateral, bilateral, regional, subregional or other multilateral channels, including relevant regional and international intergovernmental or nongovernmental organizations and financial and development institutions) for the development and strengthening of multisectoral, comprehensive tobacco control programmes of developing country Parties and Parties with economies in transition in any of the following areas:
1		development, transfer and acquisition of technology, knowledge, skills, capacity and expertise related to tobacco control?
	1	Assistance provided Yes
	2	Assistance received Yes
1		provision of technical, scientific, legal and other expertise to establish and strengthen national tobacco control strategies, plans and programmes?
	1	Assistance provided Yes
	2	Assistance received Yes
1		appropriate training or sensitization programmes for appropriate personnel in accordance with Article 12?
	1	Assistance provided Yes
	2	Assistance received Yes
1		provision of the necessary material, equipment and supplies, as well as logistic support, for tobacco control strategies, plans and programmes?
	1	Assistance provided No
	2	Assistance received No
1		identification of methods for tobacco control, including comprehensive treatment of nicotine addiction?
	1	Assistance provided No
	2	Assistance received

		No
1		promotion of research to increase the affordability of comprehensive treatment of nicotine addiction?
	1	Assistance provided No
	2	Assistance received No
D7		Please identify the Party or Parties from which assistance was received or to which assistance was provided.
D8		Please provide information about any assistance provided or received in the space below, including any support received from nongovernmental organizations (please, specify). -The DOH, through the Bureau of International Health Cooperation (BIHC), provided technical assistance as resource speaker during the Capacity Building Workshop on Article 5.3, organized by the WHO FCTC Knowledge Hub for Article 5.3 -The DOH and the Food and Drug Administration (FDA) attended the "Online Legal Training Course on Law and Noncommunicable Disease", organized by the McCabe Centre for Law -The DOH and Department of Finance (DOF) attended the WHO Tobacco Taxation Workshop, organized by the Knowledge Hub on Tobacco Taxation (in partnership with the Research Unit on the Economics of Excisable Products (REEP) -From The International Union Against Tuberculosis and Lung Disease grants funding support to Metropolitan Manila Development Authority (MMDA) for the enforcement of tobacco control policies in the region. -Johns Hopkins University offered certificate and scholarship program where MMDA Project Staff had attended
D9		If you have not received or provided assistance in any of the aforementioned areas, please identify any financial or technical assistance that may be under consideration, if appropriate.
D10		Have you encouraged relevant regional and international intergovernmental organizations and financial and development institutions in which you are represented to provide financial assistance for developing country Parties and for Parties with economies in transition to assist them in meeting their obligations under the Convention? No
D11		Please provide details in the space below.

E. PRIORITIES AND COMMENTS

E1		<p>What are the priorities for implementation of the WHO Framework Convention on Tobacco Control in your jurisdiction?</p> <p>-The focus of WHO FCTC implementation in the country are the following articles: Articles 5.2, 5.3, 6, 8, 9, 11, 12, 13, 14, 16, 17, 20. -Relative to the regulation of ENDS/ENNDS, HTPs and other tobacco products, the regulatory framework is being designed to comply with Articles 5.3, 8, 9, 10, 11, 13, 15 and 16, both on national and sub-national levels.</p>
E2		<p>Have you identified any specific gaps between the resources available and the needs assessed for implementing the WHO Framework Convention on Tobacco Control?</p> <p>Yes</p>
E3		<p>Please provide details in the space below.</p> <p>-Some national laws were identified to be inconsistent with the requirements under WHO FCTC -There is lack of knowledge among government officials and employees relative to WHO FCTC Article 5.3 and the national policy implementing the said article -The government lacks preparedness relative to the accession to WHO FCTC Article 15 Protocol -There is a need to increase and develop the capacity of the government, specifically DOH-FDA relative to the agency's expertise on tobacco product regulation -There is lack of promotion on the cessation services offered by the government -There is a need for more researches to be done for tobacco control especially on the effects of the non-combustible tobacco product -Tobacco industry interference attempts have ramped up especially with the rebranding of the industry</p>
E4		<p>What, if any, are the constraints or barriers, other than lack of resources, you have encountered in implementing the Convention?</p> <p>Priority programs in some LGUs Interference from tobacco industry</p>
1		<p>Do you have any of the following products available on your national tobacco market?</p>
	1	<p>smokeless tobacco products</p> <p>Yes</p>
	2	<p>water pipe tobacco</p> <p>Yes</p>
	3	<p>Electronic Nicotine Delivery Systems (ENDS)</p> <p>Yes</p>
	4	<p>Electronic Non-Nicotine Delivery Systems (ENNDS)</p> <p>Yes</p>
	5	<p>heated tobacco products (HTPs)</p> <p>Yes</p>
1		<p>Have you adopted and implemented any policy or regulation that is specific to the following tobacco products?</p>
	1	<p>smokeless tobacco products</p> <p>No</p>
	2	<p>water pipe tobacco</p> <p>No</p>
	3	<p>Electronic Nicotine Delivery Systems (ENDS)</p> <p>Yes</p>
	4	<p>Electronic Non-Nicotine Delivery Systems (ENNDS)</p>

		Yes
	5	heated tobacco products (HTPs)
		Yes
E7		If you have any relevant information related to questions E5 and E6, please provide details in the space below.
E8		Do you have a costed national tobacco control plan or strategy? N/A
E81		If you answered “Yes” to question E8, is this costed national tobacco control plan or strategy fully funded? N/A
E82		Please attach the costed plan or strategy here.
E9		Please provide the government’s expenditure on tobacco control, for the latest year available, in your country’s currency.
E10		Have you adopted and implemented any national legislative, executive, administrative and/or other measures that go beyond the requirements of the Convention in line with Article 2.1 (e.g, endgame strategies, smoke-free generations, tobacco free villages or cities)? N/A
E101		If you answered “Yes” to question E10, please provide details.
E11		Please attach any documentation relevant to any sections of the reporting instrument.
E12		Please provide any other relevant information not covered elsewhere that you consider important.
E13		Your suggestions for further development and revision of the reporting instrument: